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Abstract 
 
Breast cancer is the most common cancer type amongst women, and closer to 3000 
women in Norway will be diagnosed with this disease in 2012. Although major 
improvements have been achieved in the treatment, and thus the outcome, of breast 
cancer patients in the past years, little has been accomplished for those with an 
advanced disease.  
B7-H3 is an immunoregulatory protein, and its overexpression has been associated 
with advanced disease and poor prognosis in breast cancer. A previous study has 
shown that B7-H3 silencing increased Paclitaxel sensitivity in B7-H3 expressing 
breast cancer cell lines. Resistance to treatment is a general challenge in systemic 
management of advanced breast cancer, and increased knowledge about the molecules 
and pathways involved in this process is important in order to improve the outcome 
for these patients. 
To further study the function of B7-H3 and its putative involvement in lack of 
treatment response in breast cancer, we compared the efficacy of 22 different anti-
cancer drugs in two B7-H3 expressing triple negative metastatic breast cancer cell 
lines, MDA-MB-435 and MDA-MB-231, and their B7-H3 silenced counterparts. In 
particular two drugs targeting the PI3K/Akt pathway, API-2 and Everolimus, showed 
a significantly better efficacy in the B7-H3 silenced cells.  
 
To elucidate the cellular mechanisms involved in the observed sensitization in the B7-
H3 knockdown cells, we performed Western blot analysis on several proteins in the 
PI3K/Akt/mTOR pathway. The cells that did not express B7-H3 had lower levels of 
both phospho-Akt and the downstream signaling molecule phospho-p70S6K 
following drug exposure, indicating B7-H3 associated the regulation of proteins in 
this pathway. This, together with the previously observed relationships between B7-
H3 expression in metastasis and chemoresistance, suggest that this protein might be a 
therapeutic marker to increase the effect of current anti-cancer treatment, although the 
specific roles of B7-H3 in this context need to be investigated further. 
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Sammendrag 
 
Brystkreft er den vanligste krefttypen blant kvinner i Norge. Selv om store fremskritt 
har blitt gjort i behandlingen de seneste årene, er prognosen fortsatt dårlig for de 
pasientene der sykdommen har spredd seg.  B7-H3 er et immunoregulatorisk protein, 
og høyt uttrykk er forbundet med spredning og dårlig prognose i flere krefttyper, 
deriblant i brystkreft. Oppregulert B7-H3 har også blitt forbundet med resistens mot 
kjemoterapi i brystkreft cellelinjer. Resistens mot behandling er en stor utfordring 
innen kreftbehandling, og da særlig hos pasienter hvor sykdommen har spredd seg. 
Økt kunnskap om molekyler og underliggende mekanismer for resistens er derfor 
viktig for å kunne bedre behandlingen og overlevelsen av brystkreft pasienter.  
 
Vi ønsket å ytterligere undersøke den observerte sammenhengen mellom et høyt 
uttrykk av B7-H3 og mangelen på behandlingsrespons i brystkreft. Dette ble gjort ved 
å sammenligne effekten av 22 forskjellige anti-cancer medikamenter i to trippel 
negative metastatiske brystkreftcellelinjer MDA-MB-435 og MDA-MB-231 som 
uttrykte B7-H3 og som ikke uttrykte dette proteinet. Vi identifiserte to små molekyl-
hemmere, API-2 og Everolimus, som hadde bedre effekt i kreft cellene som hadde 
lavt B7-H3 uttrykk.  
 
Western blot analyser ble utført for å finne ut mer om de molekylære mekanismene 
bak den observerte B7-H3 medierte sensitivering. Ved å undersøke aktivitetsnivået av 
flere proteiner i PI3K/Akt signalveien, som spesifikt blir inhibert av disse hemmerene, 
så vi at celler som ikke uttrykte B7-H3 hadde lavere nivåer av både fosforylert Akt 
(aktiv form) og et molekyl nedstrøms for Akt, fosforylert p70S6K. Nedsatt aktivitet 
av denne signalveien fører til redusert cellevekst, og våre resultater indikerer at B7-
H3 medierer, indirekte eller direkte, regulering av proteiner i denne signalveien. 
Dette, tatt i betraktning med den tidligere observerte sammenhengen mellom høyt B7-
H3 uttrykk og metastase og kjemoresistens tyder på at proteinet kan være et mulig 
terapeutisk mål som kan øke sensitiviteten til dagens kreftmedikamenter, men den 
spesifikke rollen til B7-H3 i denne sammenhengen må imidlertid undersøkes 
nærmere. 
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Aim of study 
 
Resistance to treatment is a general challenge in breast cancer therapy, and increased 
knowledge about the underlying mechanisms and the identification of new therapeutic 
markers are important in order to improve patient outcome.  
 
B7-H3 is an immunoregulatory protein, and a high expression of this protein has been 
associated with advanced disease and poor prognosis in breast cancer, as well as in 
other types of cancer. The exact physiological role is not known, but a recent study 
showed that knockdown of B7-H3 increased the sensitivity to Paclitaxel in breast 
cancer cell lines in vitro and in vivo. The aim of the present thesis was to further study 
the role of B7-H3 in treatment response in breast cancer, in particular by;  
 
1. Further investigating the role of B7-H3 in drug resistance by performing a 
drug screen of B7-H3 knockdown breast cancer cell lines and their B7-H3 
expressing counterparts. The drug screen constituted a panel of 22 anti-cancer 
drugs, both chemotherapeutics and small molecule inhibitors,  
2. Elucidating the underlying mechanisms behind any B7-H3 induced difference 
in drug efficacy obtained from the drug screen by performing Western blot 
analysis of target proteins.  
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1. Introduction  
 
1.1 Cancer 
 
Cancer is a broad group of diseases and is characterized by uncontrolled cell growth. 
The abnormal cells may grow and divide, leading to the formation of a clump of cells, 
a tumor, that can be benign (not cancer) or malignant (cancer). A malignant tumor can 
divide and invade the surrounding tissue, and some of the cancer cells may spread 
through the blood stream or the lymphatic system and form tumors at distant sites of 
the body, a process called metastasis (1). Benign tumors lack the invasive and 
metastatic capacity of malignant tumors; however the abnormal growth may damage 
local tissue. A cancer is named after its tissue of origin, and thus a breast cancer that 
has spread to in example the lung is called metastatic breast cancer (2). This is 
because it continues to grow as a breast cancer in the foreign tissue, and this is of 
importance with respect to treatment selection. In 2008, there was an estimate of 12.7 
million new cancer cases around the world, where the most common forms were lung, 
breast (in women) and colorectal cancer (3;4).  
 
Cancer is a genetic disease where several genetic and epigenetic alterations are 
required for its development and progression (5;6). Genes encoding tumor suppressor 
genes, oncogenes and DNA repair genes are frequently mutated, as they are involved 
in mechanisms that orchestrate normal tissue growth (1). In addition, epigenetic 
alterations and small micro-RNA (miRNA) changes also contributes to the 
development of the disease (1;7).  
 
The process of tumorgenesis, the initiation and development of a tumor, is a multistep 
process where the cell gains genetic alterations followed by natural selection of its 
progenies with advantageous mutations. This drives the transformation of normal 
human cells to progressively more malignant progenies (8). Several hypotheses have 
been suggested regarding tumorgenesis and the origin of tumor heterogeneity (9). 
Nowell proposed that tumor development occurs through the clonal expansion of one 
malignant cell that, by sequential proliferation, gives rise to a heterogeneous tumor. In 
this theory, all progenies have the ability to promote sustained proliferative signaling, 
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and thus are able to propagate the tumor (10). Another hypothesis of tumor initiation 
and development is the cancer stem cell (CSC) theory (11), where a malignant cell 
with stem cell-like properties, the capacity of unlimited self-renewal, has a high 
tumorigenic potential (tumor initiating properties). This cell has the ability to form a 
heterogeneous tumor mass by asymmetric cell division, where the progenies display 
non-tumorigenic potential (11). According to this theory, the CSCs thus represent the 
small bulk of the tumor responsible for its propagation (12;13). In addition, the 
polyclonal evolution model, the self-seeding model and the mutator phenotype model 
of tumor progression and heterogeneity add additional layers of complexity to the 
biology of cancer. Importantly, studies supporting all these models imply that 
different cancers may evolve by several mechanisms (9).    
 
Although cancer is a heterogeneous and complex disease, there are several central 
capabilities that most, if not all, cancers acquire. In 2000, Hanahan and Weinberg 
proposed six alterations in cell physiology essential for malignant growth referred to 
as the hallmarks of cancer. These acquired capabilities are: 1) sustained proliferative 
signaling, 2) evasion of growth suppressing signals, 3) resisting cell death, 4) enabling 
replicative immortality, 5) inducing angiogenesis and 6) activating invasion and 
metastasis (8). In 2011, the same authors described two additional emerging 
hallmarks; the ability to reprogram the energy metabolism and the evasion of immune 
destruction. Moreover, they defined two categories of enabling characteristics which 
both facilitate the acquisition of core- and emerging hallmarks, as well as serving as a 
driving force in tumor development: genome instability and mutation and tumor-
promoting inflammation. The authors also acknowledge the contribution of the tumor 
microenvironment in cancer (14). These conceptual hallmarks serve as a framework 
in cancer biology, and are illustrated in Figure 1. 
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Figure 1. The hallmarks of cancer. The hallmarks of cancer are common traits that cancer cells must 
acquire to have the biological capacity for malignant growth as proposed by Hanahan and Weinberg. 
Central to acquiring and facilitating these cancerous properties are the enabling characteristics and the 
interaction with the microenvironment (modified from (14)).  
 
1.2 Breast cancer 
1.2.1 Breast cancer incidence and risk factors  
 
Breast cancer is the most common type of cancer in women worldwide with 1.4 
million new cases diagnosed in 2008 (4). In Norway, close to 3000 patients are 
diagnosed with this disease every year. Major development in cancer treatment and 
early detection can explain the high relative survival rate of 88 % in breast cancer 
patients (15). Early detection by mammographic screening might have an impact on 
the improved prognosis through discovering more breast cancer at a less advanced 
stage, though its putative impact on survival has not yet been confirmed. The breast 
cancer tumors are classified into different stages (from I to IV) according to their 
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aggressiveness. Despite the improvements in cancer care, little has been accomplished 
for the patients that have metastatic disease at the time of diagnosis (Stage IV), and 
these patients still have a poor 5-year survival (15) (Figure 2). 
 
 
Figure 2. The relative 5-year survival of breast cancer patients in Norway from 1970 to 2009 
according to their tumor stage. The stage of the tumor refers to the extent of the disease based on 
several factors, with a higher tumor stage the more advanced the disease is. Notice that the patients 
with tumors stage IV (metastatic disease) have little, if any, change in relative survival from 1970 to 
present day (The Figure is based on data from the Cancer registry of Norway (15)).  
The etiology of breast cancer is multifactorial, with multiple genetic, hormonal and 
environmental factors contributing to the risk of developing the disease. Hereditary 
breast cancer accounts for approximately 5-10 % of all breast cancer, thus the 
majority of breast cancer arises somatically (6). The hormonal risk factors are many, 
including age, early onset of menarche, late menopause and not having breast fed 
(16;17). All these factors contribute to the risk of breast cancer development due to 
prolonged exposure to the hormone estrogen (17). In addition environmental factors, 
such as carcinogens and UV exposure, and life style factors, such as low physical 
exercise and obesity, all contribute to the risk of developing breast cancer (15;16). In 
post-menopausal women, estrogen is synthesized by fat cells (adipocytes), and obesity 
may therefore lead to an elevated estrogen exposure (17).   
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1.2.2 The human breast anatomy and breast cancer development 
 
The human breast, or mammary gland, is situated on the rib cage above the Pectoralis 
major muscle, and the organ’s main function is to produce milk (18;19) (Figure 3). In 
the mammary gland the major developmental steps occur after birth and are related to 
puberty and reproduction (19). The mammary epithelial growth and development are 
regulated through growth hormone (GH), estrogen, progesterone and prolactin (19). 
The breast has glandular tissue consisting of 15-20 lobes, which are composed of 
many smaller structures named lobules. The lobules produce milk upon hormonal 
stimuli which is secreted through the ducts to the nipple (18). The ducts and the 
lobules have an inner layer of epithelial cells, surrounded by an outer layer of 
myoepithelial cells that are separated from the stroma by the basement membrane 
(19). The stroma consists mainly of adipose tissue, but also a variety of other cells and 
an infiltrating network of lymphatic vessels and nodes, in addition to blood vessels 
that remove waste and provide nutrition’s and oxygen to the tissue (19;20).  
 
 
Figure 3. The human breast anatomy. The structure of the female breast is mainly composed of fat, 
but also glandular tissue (adapted from (21)). 
 
Breast cancer is divided into two main categories: carcinomas in situ (CIS), which are 
enclosed by the basement membrane, and invasive carcinomas (IC). CIS may 
eventually develop to IC, and is considered the precursor of invasive cancer (2;22). IC 
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is generally separated into two main types: invasive ductal carcinoma (IDC) and 
invasive lobular carcinoma (ILC) which arises in the epithelial cells in the ducts or 
lobules of the breast, respectively. Several other subtypes exist, however IDC and ILC 
account for the majority with 70-80 % and 10-20 % of all invasive carcinomas, 
respectively (23). The progression of breast cancer will here be exemplified by the 
development of IDC, as this is the most common malignancy (Figure 4). DC develops 
through sequential steps from atypical hyperplasia, a premalignant lesion of abnormal 
cells within the ducts, to ductal carcinoma in situ (DCIS), a non-invasive lesion of 
cancer cells. At this point the tumor is still encapsulated by the basement membrane 
(24). The next step is characterized by the degradation of the basement membrane and 
invasion to the surrounding tissue, and some tumor cells may eventually progress to 
become metastatic (5).  
 
 
Figure 4. The multistep development of cancers in the ducts of the breast. The normal breast has 
ducts composed of an organized lining of epithelial cells that are surrounded by a basement membrane. 
Breast cancer is thought to progressively develop through in situ and invasive to metastatic cancer  
(available from (25)). 
 
1.3 Diagnosis, classification and treatment of invasive               
breast cancer 
 
Breast cancer is a broad group of diseases, as confirmed by molecular profiling 
studies which classified breast cancer into five distinct subgroups based on their 
genetic composition: Luminal A (ER+), Luminal B (ER+), ERBB2-enriched 
(HER2+), Basal-like and Normal-like tumors (26;27). Importantly, each subclass 
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showed different clinical outcomes (27). Current treatment of breast cancer 
appreciates the diversity of the disease, and patients are evaluated with regard to age 
and tumor characteristics to help guide the treatment. Still, the identification of new 
therapeutic and prognostic markers is important in order to identify the patients who 
will benefit from treatment, and to improve the outcome for patients with aggressive 
disease.  
 
In Norway, the diagnosis of breast cancer is based on the “triple test”. This test 
consists of a clinical examination, radiographic imaging (by mammography, 
ultrasound or MR), and a pathology test (either by fine needle aspiration or core 
needle biopsy). Tumors are pathologically evaluated and classified according to three 
distinct categories: tumor stage (by the TNM standard), histological grade and 
receptor status (the presence of the estrogen receptor, the progesterone receptor or the 
HER2 receptor), in addition to the expression of the proliferation marker Ki67 (23). 
Together, the information of these parameters has prognostic and predictive value, 
and is used to stratify individual patients for appropriate treatment according to 
guidelines provided by the Norwegian Breast Cancer Group (NBCG) (23).  
 
1.3.1 Tumors staging according to the TNM classification 
 
The staging of a breast tumor is performed on the basis of the TNM (Tumor, Node 
and Metastasis) classification system provided by the American Joint Committee on 
Cancer (AJCC) (28). The TNM staging combines information based on three 
characteristic features of malignant tumors: the primary tumor size (T), the regional 
lymph node status (N), and whether the tumor has spread to a distant organ (M). The 
T category is given a number from 1 to 3 with increasing tumor size. The N (the 
regional lymph node status) category is assigned a value from 1 to 3 increasing with 
the number of positive regional lymph nodes, and the M (metastasis) value describes 
whether the tumor has spread to other parts of the body (M1) or not (M0). These three 
parameters of the TNM system are combined to a tumor stage that ranges from 0 to 
IV (metastatic disease) (28). The different stages are important prognostic factors with 
lower tumor grade indicating a better survival (29).  
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1.3.2 Histological grade  
 
The histological grade, or tumor grade, is a measure of the tumor cells’ proliferation 
and differentiation and is based on three morphological features. These are the 
percentage of tubule formation, the degree of nuclear pleomorphism and an accurate 
mitotic count (30;31). Each feature is given a value which is summed in the total 
score ranging from 1-3. The different grades indicate how differentiated the tumor 
cells are: grade 1 which are highly differentiated tumor cells (good prognosis) to 
grade 3 which are poorly differentiated tumor cells (poor prognosis) (31). The tumor 
grade is, together with tumor size and lymph node metastasis status, the most 
important prognostic indicator for predicting the risk of distant metastasis, and thus 
when considering systemic adjuvant treatment (treatment in addition to and after 
surgery) (23).  
 
1.3.3 Receptor status  
 
Breast cancer tumors are classified according to their expression of the two hormonal 
receptors, the Estrogen (ER) and the Progesterone receptors (PR), in addition to the 
growth factor receptor HER2. The evaluation of these receptors are of clinical 
importance for treatment decision as substances targeting specific receptors have been 
developed (23). Tumors with a high expression of these receptors are called ER 
positive (ER+), PR positive (PR+) or HER2 positive (HER2+), respectively. Patients 
with ER+/PR+ tumors have the lowest risk of mortality compared to ER-/PR- tumors 
(32), and hormonal receptor status is therefore a positive prognostic marker. About 20 
% of breast cancer patients overexpress the HER2 receptor. Their clinical course is 
generally aggressive, and the expression of this protein is thus a marker of poor 
prognosis (33). However, the development of treatment targeting this receptor has 
improved the prognosis of this patient group (34). In addition, Ki-67 is used as a 
prognostic marker to evaluate the proliferative activity of breast cancer. This protein 
marker is present in all proliferative cells, and a high expression is associated with a 
higher risk of relapse and worse survival in breast cancer patients (35). 
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1.3.4 Treatment  
 
Treatment of breast cancer patients in Norway is administered according to the 
guidelines established by the NBCG, and is based on the patient’s age, genetic 
predisposition and the tumor classifications described above. The standard treatment 
of breast cancer include surgery, radiation therapy, chemotherapy, hormone therapy 
and HER2 targeted treatment (23). In general, combinations of these therapies are 
administered.  
 
The primary treatment of breast cancer is usually surgery, however, this is limited by 
both the location and size of the tumor. A main challenge in cancer treatment is the 
relapse of the primary tumor or the occurrence of distant metastasis after surgery. The 
tumor classification described above is an important tool to identify these patients, 
and to decide adjuvant treatment. 
 
Both radiation therapy and chemotherapy can be used neo-adjuvant (before surgery) 
to shrink the tumor to an operable size, adjuvant to kill any residual cancer cells after 
surgery or as palliative treatment (23). Radiation therapy uses a high energy beam 
directed to the area where the cancer cells may reside after surgery. This beam 
induces damage to the DNA of cancerous cells as well as normal cells, and is thus not 
selective. However, cancer cells are rapidly dividing, less differentiated and often 
have a reduced/defect DNA-repair system. Hence, they are more affected by the 
damage induced by radiation compared to normal cells, and this therapy has been 
shown to reduce the risk of recurrence and increase overall survival in breast cancer 
patients (36;37). 
 
Chemotherapy inhibits replication, cell division or DNA repair, thus attacking key 
features of the rapidly dividing cancer cells (38). However, the treatment is systemic, 
and therefore normal cells that are rapidly dividing are also affected. This gives rise to 
the adverse side effects of chemotherapy such as hair loss, fatigue, nausea and 
decreased production of blood cells. Women with positive receptor status are treated 
with targeted therapy, such as the anti-estrogen Tamoxifen or aromatase inhibitors for 
ER+ breast cancer patients, and the monoclonal antibody Trastuzumab for HER2 
positive breast cancer patients (23). Importantly, these therapies are directed towards 
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specific features of the cancer cell, minimizing the adverse side effects of 
conventional therapies. However, approximately 12-17 % of all breast tumors do not 
express the ER, PR or HER2 receptors, and are called triple negative (39). Hormonal 
treatment and HER2 targeted treatment is not an option for these patients, and the 
management is limited to conventional therapy (39). There is a high rate of local and 
systemic relapse associated with the patients with triple negative breast cancer 
(23;40;41), and this group is characterized by adverse prognosis and an aggressive 
clinical course (39;41;42), emphasizing the importance of identifying new therapeutic 
markers that could improve their clinical outcome. 
 
1.4 The metastatic process 
 
Metastasis, the dissemination of cells from the primary tumor and establishment of 
growth at a secondary, distant site, accounts for 90 % of all cancer related deaths 
(43;44). While a non-invasive primary tumor can be surgically resected, metastatic 
disease is almost impossible to eradicate by surgery or local irradiation also frequently 
develops resistance to the therapy given (1). 
 
Several alterations in the cancer cells’ physiology, as well as a dynamic interaction 
with the microenvironment, is required in the process of metastasis (14). The 
metastatic cascade of solid tumors is describes as a series of sequential, interlinked 
and stochastic steps (45), as illustrated in Figure 5. These include the loss of adhesion 
molecules and degradation of the basement membrane, following infiltration of the 
extracellular matrix. Next, the cancer cell must enter the blood and/or lymphatic 
system (intravasate) where it must both survive mechanical stress and evade 
destruction by the immune system. Subsequently, the cell must be able to arrest in the 
circulation at a distant organ and exit from the vasculature into the tissue 
(extravasate). To colonize, the cancer cell must adapt to the tissue, establish growth 
and induce angiogenesis (44;46). Importantly, in order for a metastasis to occur, all 
the above mentioned steps in the cascade need to be fulfilled, making metastasis a 
highly inefficient process. A minority of the cells that disseminate from the primary 
tumor will successfully establish growth at a secondary site (47).  
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Figure 5. The metastatic cascade: A) In situ cancer must B) first invade the surrounding tissue and 
degrade the basement membrane. C) Next, cancer cells must intravasate to D) the vasculature or 
lymphatic system, and must both survive mechanic stress and evade immune destruction. E) 
Furthermore, the cancer cell has to arrest at a distant organ and extravasate. F) and G) in this hostile 
environment it has to proliferate and induce angiogenesis to colonize (adapted from (48)). 
 
Two proposed models for the metastatic progression of solid tumors are the late 
dissemination model, also called the linear model, and the early disseminating model, 
also called the parallel progression model. In the late dissemination model the 
metastatic event is considered to occur late during tumor progression in the most 
advanced cancer cells in the tumor population (49). The idea is that the cells that 
disseminate escape from an established primary tumor. Indeed, for most tumors, the 
size is of prognostic value (50;51). This hypothesis is challenged by the early 
disseminating theory (49). In this model the ability of a cancer cell to metastasize is 
due to a genetic alteration established at an early time point in tumorgenesis in a 
subset of cells in the tumor population (52). This implies a genetic heterogeneity 
between the primary tumor and the metastatic lesion (51). Importantly, molecular 
profiling studies have shown data supporting both the late (53) and early (54) 
disseminating theories, and they are likely not mutually exclusive. Independent of 
~ 18 ~ 
 
when the cancer cells disseminate from the primary tumor, there is a clear tendency 
for where they metastasize. For instance, breast cancer tend to metastasize to the 
bone, liver, lung and brain (55). This property of metastasis as a non-random and 
organ specific process is not new, and was already presented by Stephen Paget in 
1889 in the so called “Seed and soil” theory (56). Paget described metastasis as an 
interplay between the cancer cells, the “seed”, and the specific organ 
microenvironment, the “soil” (56). The organ specific manner in which metastasis 
occurs may be explained by a permissive microenvironment at the distant site that 
supports the growth of the disseminating cells, for instance by secreted growth factors 
and supportive cells, in addition to intrinsic properties of the disseminating cell (43).  
 
Invasion is the first step in the metastatic process, and is one of the key features of 
malignant tumor cells. It is characterized by the loss of normal tissue constraints and 
cellular adhesion molecules, such as E-cadherin (57) This property of cancer cells 
resembles the tissue reorganization in early development: the epithelial to 
mesenchymal transition (EMT) (58), and the reactivation of EMT in cancer cells has 
been suggested as the mechanism by which they  invade and metastasize (45). EMT is 
a normal process in tissue growth and development, recognized by a loss of epithelial 
traits and the acquisition of mesenchymal cell markers. This transit is characterized by 
several reversible alterations, including change in cellular shape, increased motility, 
loss of apo-basal polarity and the down-regulation of adhesion molecules (45;59). In 
addition, the up-regulation of developmental transcription factors such as Slug, Snail 
and Twist has been linked to metastasis (58;60-62), supporting the link between EMT 
and metastasis. Another theory of the origin of the invasive properties of metastatic 
cells is the CSC theory. As previously described, this theory hypothesizes that only a 
subset of CSCs are capable of tumor propagation, thus implying that these cells must 
also be involved in the metastatic process. The rarity of CSCs in the tumor would also 
explain the inefficiency of metastasis, as only a few of the disseminating cells would 
have the capacity to colonize (1). 
 
The final step of metastasis, colonization, relies on the ability to induce angiogenesis. 
Angiogenesis is the formation of new blood vessels from the preexisting vasculature, 
and is a normal process in growth and development as well as in wound healing and 
the reproductive cycle (1). However, angiogenesis is also an important step in tumor 
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growth and in the process of metastasis (8). As the tumor reaches approximately 2-3 
millimetres in diameter, oxygen, nutrients and elimination of waste by diffusion 
become insufficient, inducing a dormant tumor state (63;64). Thus, for further growth, 
the tumor mass is dependent on the infiltration of new blood vessels (65). 
Angiogenesis relies on the activation of vascular endothelial cells (65), which is 
regulated by a change in the balance between anti-angiogenic and pro-angiogenic 
signals, “the angiogenic switch” (8;66;67) (Figure 6). These signals include a range of 
growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth 
factors and epidermal growth factors, which are secreted in the tumor 
microenvironment (65). In addition, hypoxia, the deprivation of oxygen, stimulates 
new vessel formation through the signaling of hypoxia-inducible transcription factors 
(HIFs) (66). The HIFs up-regulate many pro-angiogenic molecules such as VEGF, 
inducing a pro-angiogenic tumor microenvironment (65).  
 
 
Figure 6. The angiogenic switch. Tumor development is initially restrained by a lack of nutrition and 
oxygen. Further growth requires vascularization of the tumor, the process of angiogenesis. Importantly, 
the infiltrating blood vessels also provide a direct route for both primary and metastatic lesions to 
further metastasize (modified from (68)).  
 
 
~ 20 ~ 
 
1.5 Signal transduction in breast cancer 
 
The transduction of extracellular signals to an intracellular response is an essential 
property of multicellular organisms in order to regulate normal tissue growth and 
homeostasis (1). The binding of an extracellular ligand, for instance a growth factor, 
to a receptor on the cell membrane, leads to activation through phosphorylation of the 
intracellular domain (69). This signal is transmitted by a cascade of phosphorylations 
of downstream targets, and is ultimately propagated to the nucleus where it activates 
transcription factors involved in the regulation of cell proliferation, differentiation and 
survival. In cancer cells, many signaling pathways are frequently deregulated (70), 
which has led to the development of pathway-targeted therapy that inhibit specific 
molecules in signaling pathways. 
The phospatidylinositol-3-phosphate kinase (PI3K)/Akt pathway is frequently 
activated in human cancers, including breast cancer, by amplification, mutation or 
translocation of one of numerous components in the signaling network (71-73).  Most 
commonly this is due to an inactivating loss-of-function mutation in the gene 
encoding the tumor suppressor phosphatase and tensin homologue (PTEN), or by an 
activating gain-of-function mutation in the PIK3CA gene, encoding the catalytic 
subunit of PI3K (71;74;75). The pathway is central in many cellular processes 
implicated in cancer such as cell growth, cell cycle progression, glucose metabolism, 
migration, EMT, angiogenesis and cell survival (76;77).  
An overview over this complex pathway is illustrated in Figure 7. The PI3K/Akt 
pathway is activated upon binding of a ligand, such as a growth factor, to a receptor 
tyrosine kinase (RTK) on the cell membrane, with the subsequent activation of its 
intracellular domain (76;78).  This creates a docking site for the recruitment and 
activation of the PI3K which subsequently converts phosphatidylinositol-3,4-
biphosphate (PIP2) to phosphatidylinositol-3,4,5 triphosphate (PIP3). PIP3 has a dual 
role in activating Akt: it activates phosphoinositide dependent kinase 1 (PDK1) and 
recruits Akt to the plasma membrane (79). Here, Akt is activated by PDK1 mediated 
phosphorylation on Thr308 (73;78;80;81). The phosphorylation of Akt at Ser473 is 
required for its full activation and many enzyme candidates have been suggested for 
this modification, including the mammalian target of Rapamycin 2 (mTOR2) 
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(73;79;82). The pathway is negatively regulated by PTEN, whose action reverses the 
PIP2-PIP3 transition, and thus impedes the activation of Akt (83). The PI3K/Akt 
signaling pathway regulates a network of signaling cascades, for instance the mTOR1 
pathway, which induces cell growth through activation of p70S6K, and inhibition of 
4EBP1, which promotes protein synthesis. Activated mTOR1 is central in regulating 
cell growth and homeostasis, and is commonly implicated in cancer (84). 
Furthermore, the PI3K/Akt pathway has been demonstrated to be involved in 
chemoresistance in ovarian and breast cancer (85;86). The PI3K/Akt signaling 
network therefore represents a promising target for cancer drug discoveries either by 
preferentially killing cancer cells or sensitizing them to conventional 
chemoterapeutics (71;86).  
 
Figure 7. The PI3K/Akt pathway regulates many cellular properties. The pathway transduces 
extracellular signals such as integrins, cytokines and growth factors from the cell membrane to the 
nucleus through the phosphorylation of numerous proteins (76;78). Akt kinase is at a nodal point in this 
network (available from (87)). 
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1.6 Resistance to anti-cancer drugs  
 
Chemotherapy represents a major therapeutic management of breast cancer, and a 
major challenge of systemic treatment is the emerging resistance by tumors, in 
particular by metastatic disease, to treatment.   
 
Chemoresistance may be an intrinsic property of the cancer cell, or it may develop 
during treatment. A property of acquired resistance is that it frequently induces a 
broader resistance to other drugs with different mechanisms of action, rendering the 
metastatic cells multi-drug resistant (38). There are many factors involved in 
chemoresistance, and both the limitations of drugs reaching the center of the tumor 
and the tumor micro-environment, contribute to the lack of effect of systemic 
treatment. In addition, there are several cancer cell specific resistance mechanisms 
such as increased drug efflux, decreased drug influx, drug inactivation, alterations in 
drug target, processing of drug-induced damage and evasion of apoptosis. These 
cellular properties of chemoresistance are illustrated in Figure 8 (38).  
 
 
Figure 8. The cancer cell specific mechanisms of resistance to chemotherapy and anti-cancer 
drugs; decreased drug influx, increased drug efflux, increased drug inactivation, alterations in the drug 
target, antagonizing drug-induced damage, here illustrated by an increased DNA-repair and evasion of 
apoptosis (38).  
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The growing understanding of cancer cell biology has led to the emerging field of 
targeted therapy, which aims to kill cancer cells specifically, by targeting molecular 
mechanisms that are critical for the cancer cells’ growth and survival. However, many 
of the cellular mechanisms involved in chemoresistance are also able to render the 
tumor cells resistant to small molecule inhibitors. In addition, an extensive crosstalk 
between multiple pathways in the cell may counteract the effect of small molecule 
inhibitors by compensatory mechanisms. Clearly, understanding the molecular 
mechanisms that influence response has great therapeutic value. This would allow 
rational combinations of different anti-cancer therapies, where targeted agents can be 
used in combination with other anti-cancer drugs to increase their efficacy (38). 
 
1.7 The B7-H3 protein, a member of the B7/CD28 family of 
co-stimulatory proteins  
 
B7-H3 (CD276) is a member of the B7 family of co-stimulatory ligands. A high 
expression of this protein has been associated with advanced disease and poor 
prognosis in several tumor forms, including breast cancer (88;89). B7-H3 is the focus 
in the present thesis, and will thus be further described in this section.  
 
The B7 family consists of 7 members of immunoregulatory ligands (B7-1, B7-2, B7-
H2, B7-H1, B7-DC, B7-H3 and B7-H4) which display both inhibitory and 
stimulatory effects with regard to T cell activation (90). Each ligand and their 
corresponding receptor are schematically illustrated in Figure 9.  
 
The activation of a T cell depends on its interaction with an antigen, in addition to 
costimulatory signals delivered by the B7 family of ligands through cognate receptors 
on the T cell membrane. The B7 family are transmembrane proteins (with the 
exception of B7-H4), that show a high degree of structural conservation. They have 
an immunoglobulin variable (IgV)-like and an immunoglobulin constant (IgC)-like 
domain in their extracellular region, a transmembrane region and a cytoplasmic tail 
(91).  
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Figure 9: An overview of the B7 family of immunoregulatory ligands. The T cell is activated 
through interaction with the MHC complex and an antigen on an antigen-presenting cell, in addition to 
an integration of signaling through the B7 familiy of co-stimulatory receptors. 
 
The B7-H3 protein was identified as a member of the B7 family in 2001 (92). It 
consists of 534 amino acids and has a molecular weight of approximately 100 kDa. 
The high molecular weight is attributed to the fact that the protein is highly 
glycosylated (93). The ligand exists in two different isoforms: the 2IgB7-H3 and the 
4IgB7-H3, with the latter containing two constant and two variable domains, and is 
the dominant isoform expressed in human tissues (90). The expression of B7-H3 is 
inducible on antigen presenting cells, T cells and natural killer cells (88). In addition, 
the protein is expressed on cells within non-lymphoid organs and at a high expression 
level in a variety of cancer types (88).  
 
Initially, the expression of B7-H3 was shown to correlate with T-cell activation and 
IFN-gamma production (92). However, contrasting studies have showed both 
stimulatory and inhibitory effects of B7-H3 on T-cell response and anti-tumor activity 
(92;94-96). Moreover, multiple studies have correlated a high B7-H3 expression with 
disease spread and poor outcome in different cancer types (89;97;98).   
 
The conflicting roles of B7-H3 may be explained by several factors. The cognate 
receptors have not been identified. Although the triggering receptor expressed on 
myeloid cells-like receptor 2 (TLT-2) has been suggested as the receptor for B7-H3 
(99), this was not confirmed by physical interaction studies performed by Leitner et al 
(94). The identification of its receptor(s) could help unravel the contrasting role of 
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B7-H3 in immune response. However, it is likely that B7-H3 might interact with 
several proteins, accounting for its diverse functions in different tumors. The 
expression patterns of these receptor(s) may also influence the immune modularly 
role exerted by B7-H3. In addition, several studies on B7-H3 are based on mouse 
models, and there are uncertainties with regard to whether these effects can be 
extrapolated to humans (88).  
 
Although most studies on the adverse effects of high B7-H3 expression in cancer is 
related to its immunoregulatory role, recent studies have identified novel non-
immunological function of B7-H3 in metastasis and chemoresistance. A high B7-H3 
expression has been associated with increased tumor cell migration and invasion in 
vitro and in vivo, thus contributing to the metastatic capacity of cancer cells 
(100;101). Another study showed that B7-H3 expression was involved in Paclitaxel 
resistance in B7-H3 expressing breast cancer cell lines both in vitro and in vivo (102). 
It remains to identify the exact physiological role of B7-H3 in normal tissue, and 
cancer. However, its implications in malignant processes and the elevated expression 
on a wide range of tumor forms make it a putative prognostic and possibly therapeutic 
target.  
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2. Material and methods 
 
All methods used in this thesis are described below, the reagents and equipments 
utilized are listed in Appendix A. 
 
2.1 Breast cancer cell lines 
 
Two breast cancer cell lines, MDA-MB-435 and MDA-MB-231, were used in this 
thesis. The cell lines were originally purchased from the American Type Culture 
Collection. Both cell lines are triple negative (ER-, PR- and HER2-) metastatic breast 
cancer cell lines with a high expression of the B7-H3 protein. B7-H3 silenced models 
of these cell lines have previously been established using stable short hairpin (sh) 
RNA with HuSH 29mer short hairpin RNA (shRNA) constructs against B7-H3 
(shB7-H3) and control plasmid pRS nontargeted TR30003 (TR33) (Origene 
Technologies, Inc, USA). Selection with 0.5 mg/µl puromycin was used to isolate 
successful clones (102). Cells with B7-H3 knockdown are referred to as shB7-H3 and 
their vector control counterparts are referred to as TR33 in this thesis. The TR33 cells 
contain a non-targeting RNA sequence and express the B7-H3 protein. This model 
system, with the MDA-MB-435 and MDA-MB-231 cell variants TR33 and shB7-H3, 
allowed the investigation of the possible involvement of B7-H3 in resistance to anti-
cancer drugs and the investigation of molecular mechanisms behind any putative 
different efficacy.  
 
2.2 Cell culturing 
 
Cell culturing was performed in sterile conditions in a laminar flow hood (LFH), 
which was disinfected with 75 % ethanol prior to use to prevent infections. Only one 
cell line was kept in the LFH at the time, and the LFH was disinfected between 
working with different cell lines. Gloves were used at all times, and all equipments 
were disinfected with 75 % ethanol before entering the LFH. Growth medium was 
heated to 37
0
C prior to use. In addition, all cells where grown on tissue-culture treated 
100x20 mm Corning Petri dishes (Corning Incorporated, NY USA). The cell lines 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (4,5 g/l glucose, 
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without L-Glutamine, SIGMA-ALDRICH
®
, USA) supplemented with 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Invitrogen, Life 
Technologies
TM
, USA), 10% fetal bovine serum (FBS) (GIBCO
®
, Life 
Technologies
TM
, USA), 5mL GlutaMAX (GIBCO
®
, Life Technologies
TM
, USA), 
Penicilin and Streptomycin (5mL, 5000 U pen/mL, 5000 U strep/mL) (GIBCO
®
, Life 
Technologies
TM
, USA) and 0.5µg/mL puromycin (10mg/mL, SIGMA-ALDRICH
®
, 
USA) and incubated in NuAire Automatic CO2 incubator (NuAire, USA) at 37
0
C with 
5% CO2.  
 
Cells were obtained from a liquid nitrogen tank where they had been stored at -170
0 
C 
in a solution containing growth medium and 5 % Dimethyl Sulfoxide (DMSO) 
(Thermo Scientific, USA). DMSO is a cryopreservant and may be harmful to cells at 
room temperature, and the transfer to fresh medium and subsequent centrifugation 
was performed quickly to prevent toxic effects of DMSO on the cells. The cell pellets 
were transferred to 15 mL Sarstedt tubes (Sarstedt, USA) containing 8mL growth 
medium, following centrifugation at 800 rpm for 8 min in a Rotina 420 centrifuge 
(Hettichlab, Germany). The supernatant was discarded and the cell pellet resuspended 
in growth medium and plated on Corning Petri dishes and incubated at 37
0
C with 5% 
CO2 saturation. All cells were grown for 2 weeks prior to conduction of experiments 
to ensure that they were stable and not damaged by the freezing or thawing.  
 
Renewal of medium was performed by discarding old medium and adding 10 mL of 
fresh medium to the Petri Dish. Cell lines, when they reached a confluence level of 
approximately 80% as observed by an Axiovert 40 inverted microscope (Carl Zeiss, 
Germany), were split by discarding old medium, and subsequently washing the Petri 
dish with 3 mL Dulbecco’s Phosphate buffered Saline (DPBS) (1X, Invitrogen, Life 
Technologies
TM
, USA) to remove remaining medium. The cells were detached from 
the Petri dish by adding 1.5 mL 0.25 % Trypsin EDTA (GIBCO
®
, Life 
Technologies
TM
, USA) for 4 minutes at 37
0
C. The medium contains divalent ions, 
such as Mg
2+
 and Ca
2+
, in addition to proteins that inhibit Trypsin. By washing with 
PBS, the remains of the medium were removed. The EDTA supplemented in the 
Trypsin solution is also a chelator that binds remaining ions. When the cells were 
detached from the Petri dish, as observed in the Axiovert 40 inverted microscope, 
growth medium was added to inhibit Trypsin activity. The cells were subsequently 
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transferred to 15 mL Sarstedt tubes and centrifuged at 800 rpm for 8 minutes. The 
supernatant was discarded and the cell pellet resuspended in growth medium and 
diluted to obtain the appropriate sub-culturing ratio. The cells were replated on new 
Petri dishes containing 10 mL growth medium and incubated at 37
0
C and 5% CO2 
saturation. 
 
2.3  Cell counting using hemocytometer 
 
The cells were counted using a Bürker hemocytometer in both the optimizing 
procedure and the drug screening procedure. The hemocytometer and the cover slip 
were cleaned by washing with 75 % ethanol and then rinsed with distilled water. Cells 
were detached from the Petri dish by trypsinating and spun down as described above. 
The old medium was discarded, and the cell pellet resuspended in 8-10 mL growth 
medium. As any groups of cells that are attached together are counted as one, it was 
important that the cells were thoroughly suspended in order to achieve an accurate 
count. 10µl of the cell suspension was then carefully applied to a Bürker chamber and 
covered with a cover-slip. Five of the squares were utilized for counting, and an 
average of these was used to calculate the number of cells in the suspension. To 
achieve a representative count it was important that each square contained between 
40-100 cells and that there was a low variance between the counted squares. The 
volume suspension in one square equals 0.1 µl and the total amount of cells per mL in 
the suspension was thus the average cell count x 10 000.  
 
2.4 The Cell titer glo® (CTG) Luminescent cell viability 
assay 
 
The CTG luminescent cell viability assay (Promega, USA) was used as an endpoint of 
the optimizing and drug screening procedures as a quantitative method to determine 
the number of metabolically active cells. The CTG reagent has two distinct properties; 
it causes cell lysis and thus the release of ATP from the cells. The ATP converts 
Luciferin to Oxyluciferin and a luminescent light, catalyzed by the Luciferase 
enzyme, as illustrated in Figure 10. The amount of luminescence is directly 
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proportional to the amount of ATP in the cells, and thus gives a quantitative 
measurement of cell viability (103). 
 
 
Figure 10. The luciferase reaction. Lucuferin is converted to Oxyluciferin and luminescence in the 
presence of ATP, cellular oxygen and the cofactor Mg
2+
. The amount of luminescence produced is 
directly proportional to the amount of ATP in the cells (103). 
 
2.5 Optimizing of cell lines for growth in 384 well plates 
 
In order to achieve the optimal cell number to apply to each well in the drug 
screening, the cells were optimized for growth in 384 well plates (Greiner bio-one, 
North-America). The cell lines MDA-MB-435 (TR33 and shB7-H3) and MDA-MB-
231 (TR33 and shB7-H3) were seeded in the 384 well plates at different dilutions, 
ranging from 300 to 1200 cells per well, depending on the proliferative rate of the cell 
lines. 50 µl of each dilution was applied to the 384 well plates in seven replicas. The 
outer wells were avoided due to an increased risk of evaporation. The plates were 
subsequently placed in open zip-lock bags with a moist tissue (dH2O) in the opening 
of the bag to avoid evaporation of nutrient medium, and then incubated for five days 
at 37
0
C and 5% CO2 saturation. At day five the cells were lysed by adding 20 µl CTG 
to each well, and incubating at room temperature for 35 minutes. The plates were 
covered with aluminum foil, as the assay is light sensitive. Luminescence was 
measured using Wallac 1450 MicroBeta TriLux luminescence counter (PerkinElmer, 
USA) with the MicroBeta Windows Workstation (PerkinElmer, USA). The 
MicroBeta Trilux is a multi-detector instrument designed for the detection of 
luminescence in microplates. The counter has two detectors that register luminescence 
from the top to the middle of the plate, and from the middle to the bottom of the plate. 
Reliable results were assured by calculating standard deviations of all measurements. 
The results were analyzed by making growth curves in Microsoft Office Excel (2007). 
~ 30 ~ 
 
The cell numbers where the cells appeared to be in logarithmic growth phase were 
chosen for drug screening.  
 
2.6 Drug screening of B7-H3 expressing and B7-H3 silenced 
breast cancer cell lines 
2.6.1 Description of the drugs screened and plate annotation. 
 
A panel of 22 different anti-cancer compounds targeting receptor tyrosine kinases and 
their downstream pathways was used in the drug screening, in addition to drugs 
targeting the estrogen receptor (4-Hydroxytamoxifen), protein complexes, and 
enzymes: topoisomerase II (Bortezomib), proteasome (Doxorubicin hydrochloride) 
and the Heat Shock Protein 90 (HSP90) (Radicicol). Drugs and their targets in the 
cell, including their concentrations, are presented in Table 1. The drug plates were not 
commercially available but were provided frozen in sealed 384 well plates by our 
collaborator, Medical Biotechnology, VTT Technical Research Center of Finland. 
The different compounds had been printed onto a 384 well plate with the Hamilton 
Microlab Star Robot (Hamilton Robotics, Switxerland). Each drug was printed in 
duplicate on the plate at seven dilutions with 10 times increment in concentration 
from the middle of the plate to the border, as illustrated in Figure 11. The edges of the 
plates were filled with DMSO and thus not utilized for the screening procedure due to 
the risk of evaporation from the outer wells. Drug screening was performed twice for 
each cell line at separate days, and with cell numbers obtained from the optimizing 
procedure.  
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Table 1: The panel of 22 drugs used in the drug screening. The target site of the drug is noted, 
together with the lowest and the highest concentration of the drug printed to the plates.  
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
 
                        
 20µ 20µ 20µ 8µ 20µ 20µ 20µ 20µ 20µ 20µ 20µ 20µ 20µ 20µ 20µ 5,2µ 20µ 20µ 20µ 20µ 340n 5µ  
 2µ 2µ 2µ 800n 2µ 2µ 2µ 2µ 2µ 2µ 2µ 2µ 2µ 2µ 2µ 520n 2µ 2µ 2µ 2µ 34n 500n  
 200n 200n 200n 80n 200n 200n 200n 200n 200n 200n 200n 200n 200n 200n 200n 52n 200n 200n 200n 200n 3,4n 50n  
 20n 20n 20n 8n 20n 20n 20n 20n 20n 20n 20n 20n 20n 20n 20n 5,2n 20n 20n 20n 20n 340p 5n  
 2n 2n 2n 800p 2n 2n 2n 2n 2n 2n 2n 2n 2n 2n 2n 520p 2n 2n 2n 2n 34p 500p  
 200p 200p 200p 80p 200p 200p 200p 200p 200p 200p 200p 200p 200p 200p 200p 52p 200p 200p 200p 200p 3,4p 50p  
 20p 20p 20p 8p 20p 20p 20p 20p 20p 20p 20p 20p 20p 20p 20p 5,2p 20p 20p 20p 20p 0,34p 5p  
 20p 20p 20p 20p 20p 5,2p 20p 20p 20p 20p 20p 20p 20p 8p 20p 20p 20p 20p 20p 20p 5p 0,34p  
 200p 200p 200p 200p 200p 52p 200p 200p 200p 200p 200p 200p 200p 80p 200p 200p 200p 200p 200p 200p 50p 3,4p  
 2n 2n 2n 2n 2n 520p 2n 2n 2n 2n 2n 2n 2n 800p 2n 2n 2n 2n 2n 2n 500p 34p  
 20n 20n 20n 20n 20n 5,2n 20n 20n 20n 20n 20n 20n 20n 8n 20n 20n 20n 20n 20n 20n 5n 340p  
 200n 200n 200n 200n 200n 52n 200n 200n 200n 200n 200n 200n 200n 80n 200n 200n 200n 200n 200n 200n 50n 3,4n  
 2µ 2µ 2µ 2µ 2µ 520n 2µ 2µ 2µ 2µ 2µ 2µ 2µ 800n 2µ 2µ 2µ 2µ 2µ 2µ 500n 34n  
 20µ 20µ 20µ 20µ 20µ 5,2µ 20µ 20µ 20µ 20µ 20µ 20µ 20µ 8µ 20µ 20µ 20µ 20µ 20µ 20µ 5µ 340n  
                        
 
 11  12  13  14  15  16  17  18  19  20  1  2  3  4  5  6  7  8  9  10  22  21 
 
Figure 11. Plate design for the drug screening. Drugs were printed in two replicates with increasing 
concentration starting from the middle of the plate (light colors) towards the edge (dark colours). The 
different dilutions ranging from 20 pM to 20 µM except blue; 8 pM - 8 µM, orange; 52 pM - 5.2 µM, 
green; 5 pM – 5 µM and purple; 0.34 pM – 340 nM. The numbers at the borders represent the drugs in 
the location, and are presented in Table 1. The outer wells contained DMSO.    
Site 
Number on 
plate 
Compound 
Lowest 
concentration 
(pM) 
Highest 
concentration 
(µM) 
HER2 
22 Herceptin 5 5 
17 Symansis CP-724714 20 20 
EGFR 
18 Gefitinib 20 20 
14 PD153035 hydrochloride 20 20 
EGFR + HER2 
5 BIBW2992 20 20 
15 Lapatinib (GW572016) 20 20 
pan-ErbB 11 CI-1033 20 20 
PI3K + mTOR1 8 PI 103 hydrochloride 20 20 
PI3K 13 Wortmannin 20 20 
Hsp90 2 Radicicol 20 20 
AKT/PKB 
1 Akt1/2 kinase inhibitor 20 20 
6 API-2 20 20 
mTOR1 
12 Everolimus 20 20 
19 Temsirolimus 20 20 
MEK/ERK 
4 PD 184352 8 8 
9 UO126 20 20 
ER 20 4-hydroxytamoxifen 20 20 
Proteasome 16 Bortezomib 5.2 5.2 
Topo2 10 doxorubicin hydrochloride 20 20 
IGFR 3 AG 538 20 20 
VEGFR 
7 AAL-993 20 20 
21 Bevacizumab 0.34 0.34 
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2.6.2 The drug screening procedure in 384 well plates 
 
All cells were healthy and had reached a confluence level of approximately 80 % 
before they were applied to the drug screening assay. The handling of the drug plate 
was done according to the health and safety procedure of the lab: A special LFH was 
utilized and nitrile gloves were worn at all times, and the plates were kept in the LFH 
at all times between handling. The LFH was covered with Versi-Dry Lab-Soakers 
(Nalgene, Thermo Scientific, USA) and the plate and all equipments were kept on this 
sheet at all times. All areas that had been in contact with the drug plate were washed 
with ethanol. Furthermore, all equipments, gloves and the drug plates were placed in a 
zip-lock bag and disposed of in an appropriate container for cytostatic waste after use, 
according to the health and safety procedures in the laboratory.  
 
The drug screening plate was thawed at room temperature for 30 minutes prior to use, 
and then centrifuged for 1 minute at 1000 rpm to spin down the drugs. The optimum 
cell number obtained from the optimization procedure was prepared by counting with 
a hemocytometer as described previously. The plates were unsealed using a Combi 
Thermo sealer (ABgene, UK), and 50 µl cell suspension was dispensed to each well 
by a Multidrop Reagent dispenser Combi (Thermo Fischer Scientific, USA) 
(Adjustments: 384 well plate standard, 15 mm, 50 µl standard tube cassette, speed: 
low). The reagent dispenser was washed with distilled water (GIBCO
®
, Life 
Technologies
TM
, USA), ethanol (75%) and distilled water before and after use. In 
addition, initial priming with cell suspension was done to control the flow in all eight 
tubes. By applying the cell suspension with a reagent dispenser, error due to manual 
pipetting was reduced. The 384 well drug plate was subsequently placed in an open 
zip-lock bag with a moist tissue to prevent dehydration and incubated for five days at 
37
0
C and 5% CO2 saturation. At day five the plates were placed in the LFH for 30 
minutes to reach room temperature before adding 20 µl CTG by the reagent dispenser 
(Adjustments; 384 standard, 15 mm, 20 µl standard tube cassette, speed low). The 
plate was covered with aluminium foil to protect the CTG from light exposure and 
then incubated for 35 minutes in the LFH. After incubation with CTG, the drug plate 
was transported to the luminescence counter in a Nalgene Bio Transport Carrier 
(Nalgene, NY, USA) designed to transport potentially hazardous material, to a Wallac 
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luminescence counter where the luminescence was measured. The workflow of the 
drug screening assay is illustrated in Figure 12. 
 
 
 
Figure 12. The workflow of drug screening procedure in 384 well plates. The drugs were printed 
onto 384 well plates, and the cell suspension was added using a Multidrop Combi (Thermo Fischer 
Scientific, Finland). The plates were subsequently incubated for five days at 37°C with 5 % CO₂. At 
day five the cells were lysed with the Cell Titer-Glo (CTG) luminescent Cell Viability Assay. CTG 
measures ATP in the cells, and thus gives a quantitative measurement of cell viability. 
 
2.7 Statistical analyses and growth inhibition curves 
 
To investigate the effect of B7-H3 knockdown on drug response the drug efficacy was 
evaluated by comparing the response of B7-H3 knockdown cells to their B7-H3 
expressing counterparts (i.e. MDA-MB-435 shB7-H3 compared to TR33, MDA-MB-
231 shB7-H3 compared to TR33). All data was normalized to cells growing at the 
lowest drug concentration before any statistical analysis was calculated, and the 
normalized data is referred to as the relative response. Hence, the measurement at the 
lowest concentrations was excluded from further analysis. Statistical significance was 
assessed by performing a two-tailed Student’s (Excel, Microsoft Office Excel (2007), 
Seattle, WA, USA). This test evaluates the differences in means of two datasets. The 
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test calculates a p-value, which is the probability of obtaining a test statistic (a 
difference in means) as extreme as the one observed given that there is no difference. 
A low p-value thus implies a low probability of obtaining the given results by random 
chance and all p-values below 0.05 were considered statistically significant. The 
growth inhibition curves were made by plotting the relative response versus the drug 
concentration using the Graphpad prism software (Graphpad Prism Software Inc., 
USA). The curves were log transformed, and EC50 values calculated from curves that 
followed a sigmoid curve (S-shaped).  
 
2.8 Treatment of MDA-MB-231 and MDA-MB-435 cell 
variants with API-2 and Everolimus 
 
To further investigate the molecular mechanisms behind the differences in drug 
response to selected drugs, Western blot analysis was performed on protein targets in 
the pathway affected by the small molecule inhibitors. MDA-MB-231 and MDA-MB-
435 cell variants, TR33 and shB7-H3, were investigated with respect to differences in 
the activity levels of proteins at different time points after treatment.  Cells were 
plated at appropriate cell number and treated the subsequent day with drug 
concentrations obtained from the drug screening assay. MDA-MB-435, TR33 and 
shB7-H3, were treated with API-2 (20 µM) (SIGMA-ALDRICH
®
, USA) and 
harvested at time: 0 hours (no treatment), 0.5 hours and 2 hours. MDA-MB-231, 
TR33 and shB7-H3, were treated with API-2 (2 µM) and harvested at time: 0 hours 
(no treatment), 0.5 hours and 2 hours. MDA-MB-231, TR33 and shB7-H3, were in 
addition treated with Everolimus (200 nM) (SIGMA-ALDRICH
®
, USA) and 
harvested at time: 0 hours (no treatment), 0.5 hours and 2.  
 
2.9 Harvesting of cells 
 
The old medium was discarded and the cell culture flask placed on ice. 3 mL cold 
PBS supplemented with phospho-STOP Phosphatase inhibitor cocktail tablets (Roche, 
Germany) was added to the flask and the cells were detached by gently scraping the 
base of the flask with a cell scrape (TPP Techno Plastic Products AG, Switzerland). 
The cell suspension was transferred to a 50 mL Sarstedt tube and centrifuged in a 
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Heraus Labofuge 400R (Thermo scientific, USA) at 1200 rcf for 5 minutes at 4
0
C. 
The supernatant was discarded, and the cell pellet washed by resuspending in 1 mL 
phospho-STOP supplementet PBS and transferred to 1.5 mL eppendorf tubes. The 
samples were subsequently centrifuged in a Spectrafuge
TM
 24D Digital 
Microsentrifuge (Labnet international, USA) at 14 000 rpm for 5 minutes at 4
0
C, the 
supernatant were discarded and the dry pellets subsequently stored in a freezer at -80 
0
C or directly lysed. 
 
2.10 Cell lysis 
 
The cells were lysed to obtain their protein contents. In this thesis, protein activity 
levels were measured with regard to phosphorylated proteins. Protein modification by 
phosphorylation leads to their activation or inactivation, and is a dynamic and 
transient alteration regulating protein activity in many cellular processes. The 
phosphate group can thus easily be removed by phosphatases intrinsically present in 
the cells. To maintain the proteins in their phosphorylated state and prevent potential 
degradation of proteins, the lysis buffer (LB) (Appendix B) was supplemented with 
broad spectrum inhibitors of phosphatises and proteases that are endogenous present 
in the cell lysate. In addition, the LB also contained an appropriate buffer solution and 
substances that disintegrated the cytoplasmic membranes of the cells’ compartments. 
The cells were lysed with LB, and the amount used was dependent on the size of the 
cell pellets (varied between 10-50µl), and subsequently placed on ice for 20 minutes. 
The samples were then sonicated using an Ultrasonic homogenizer (Cole-Parmer 
4710 series, Chicago, USA) three times for five seconds at 4
0
C, and incubated at -
80
0
C for 5 minutes. The sonication and the freezing further disintegrated the cell 
membranes and other cellular structures mechanically, and released the protein 
contents of the cells. Further, the cell pellets were centrifuged for 15 minutes at 
14 000 rpm and 4
0
C in a Microcentrifuge. The supernatant was retained and protein 
concentrations measured by the BCA assay.    
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2.11 Measuring protein concentrations by the BCA assay 
 
The Pierce® BCA Protein Assay Kit (Thermo Scientific, USA) was utilized to 
measure protein concentrations in the cell lysate. This is a quantitative method to 
determine protein concentration based on the Biuret reaction and the reaction of 
cuprous ions with Bicinchoninic acid (BCA). The BSA standards were prepared 
according to the protocol provided by the manufacturer and are attached in Appendix 
B  (104).   
 
Samples and LB (blank test) were diluted 20 times (3 µl sample/LB solution + 57 µl 
dH2O). Subsequently, 25 µl of each Bovnie serum albumin standard dilution (A-F), 
sample and blank were pipetted in duplicate on a Corning
®
 Costar
®
 96 well cell 
culture plate (Corning Incorporated, SIGMA-ALDRICH, USA). The working reagent 
(WR) was prepared by mixing 50 parts of BCA Reagent A (containing an alkaline 
environment, BCA and Sodium Tartrate) with one part of BCA reagent B (containing 
4 % cupric sulphate). 200µl of WR was added to each well followed by 30 minutes 
incubation at 37 
0
C in a Termaks drying oven (Termaks, VWR, USA). This provided 
the appropriate conditions for the biuret reaction where Cu
2+
 first chelates with 
peptides containing three or more amino acid residues in an alkaline environment, a 
reaction that results in the reduction from cupric to cuprous ions. Secondly, the BCA 
forms a deep purple colour complex with Cu
+1
. This complex is water-soluble and its 
colour intensity is directly proportional to the protein concentration in the solution 
(105). The reaction exhibits a strong linear absorbance at 568nm with increasing 
protein concentration within a working range of 20-2.000µg/mL (104). The 
absorbance was measured with the Wallac Victor
2
 1420 Multilabel Counter 
(PerkinElmer, USA) with the Wallac 1420 workstation at 540 nm, and the averages of 
the blank standard replicates were subtracted from all measurements. The correct 
calculation of protein concentration was based on a standard curve prepared in 
Microsoft Office Excel (2007) by plotting measured blank-corrected BSA standard 
absorbencies to their concentration (µg/mL). The concentrations of the samples were 
calculated by means of the equation of the linear regression (y = ax + b) to this curve.  
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2.12 Western blot 
 
The Western blot procedure separates proteins based on their size as they migrate 
through a polyacrylamide gel, and subsequently transfer the proteins to a membrane 
where they can be stained by antibodies for protein detection. An overview of the 
entire procedure is presented in Figure 13.  
 
 
Figure 13. The outline of the Western blot procedure: A) the protein is linearized and gets a net 
negative charge by adding SDS and heat, B) samples are loaded to a gel, a ladder (size marker) is 
added to well one, C) an electric current is applied to the gel and smaller proteins will migrate fast than 
larger proteins through the gel network, enabling the protein separation based on size, D) proteins are 
electrotransferred to a PVDF membrane, E) the membrane is blocked to avoid unspecific binding, and 
primary antibody specific for the relevant protein (green) is added, F) secondary HRP-coupled protein 
is added, which recognize and bind to the primary antibody, G) HRP-substrate is added and H) The 
luminescent light is detected in a imaging machine.  
 
The procedure can be divided into several steps described underneath.  
 
Step 1: Preparation of protein samples for loading on the gel and 
separation by SDS-PAGE 
 
The protein lysates were kept on ice while preparing the samples. The required 
sample volume was calculated from the BSA assay to achieve a final protein loading 
concentration of 20µg. 2µl NuPage
®
 Sample Reducing agent (10x) (RA) (Life 
Technologies
TM
, USA) and 5µl NuPage
®
 LDS Sample Buffer (4x) (LB) 
(Invitrogen
TM
, Technologies
TM
, USA) were added to the protein samples and 
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supplemented with dH2O to reach a final sample volume of 20 µl. Subsequently, the 
proteins were denatured by incubating the samples on a Grant Dry Block Heater 
(QBD2) (Grant, USA) for 5 minutes at 95 
0
C, and then quickly centrifuged in a 
Micro120 Centrifuge (Hettich, Germany) for 1 min, at 12 000 rpm. In these steps, a 
net reduction of the proteins in the samples was obtained by adding the RA, thus 
breaking the cystein bonds in the proteins. Subsequent heating further denaturized the 
proteins, ensuring that they were in a linear form. This enabled the separation of the 
proteins according to size when migrating through the network of the gel (Figure 13 
A). The LB contains glycerol, ensuring that each sample sinks to the bottom of the 
well when applied onto the gel. A NuPage® Bis-Tris (4-12%, 0.1mm x 10 well, Life 
Technologies
TM
,
 
USA) polyacrylamid gel was mounted in an XCell SureLock
TM
 
Mini-Cell (Life Technologies
TM
, USA). The inner concealed compartment and the 
surrounding compartment were filled with Running Buffer consisting of 50 mL 
NuPage® MES SDS Running Buffer (20x) (Life Technologies
TM
, USA and 950 mL 
dH2O. 10 µl SeeBlue®Plus2 Prestained Standard (1x) (Invitrogen, Life 
Technologies
TM
, USA) was used as a molecular weight reference, and 20µl of each 
sample was loaded onto the gel.  An overview over mounting of the electrophoresis 
chamber is illustrated in Figure 14.  Electricity was applied to the system using a 
Power Pac 300 (BioRad, USA) at 105 V. This separated the negatively charged 
proteins as they migrated towards the positive pole. The velocity at which the proteins 
travel was dependent on their size, with smaller proteins migrating faster (Figure 13.B 
and C). When applying electricity, bubbles from the bottom of the inner chamber 
confirmed that the system was working. After 10 minutes the voltage was adjusted to 
150 V, and the gel was run for approximately 1.5 hours, depending on the protein 
targeted for the separation.  
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Figure 14. The setup of XCell Surelock
TM
 Mini-Cell for separation of proteins by SDS-Page. Each 
step in the setup is described (adapted from (106)). 
 
Step 2: Transferring the proteins to a Polyvinylidene difluoride 
(PVDF) membrane 
 
In the second step the proteins were electro transferred to a PVDF membrane (Figure 
13 D). Prior to use the pads and Watman
TM
 chromatography papers (3mm, GE 
Healthcare, England) were soaked in blotting buffer (50 mL MeOH, 10 X 
blottingbuffer (30.3 g Tris (Bio-Rad, USA), 144 g Glycin (Merck, Germany), 1L 
dH2O) + dH2O to a final volume of 500 mL), and Immobilon® Transfer Membranes 
Polyvinylidene Difluoride (PVDF) (0.45µm pore size, Millipore, Germany) were 
activated in Methanol for 1 minute. The pads, watmans, gel and membrane were 
carefully placed into a transfer cell (XCell II
TM 
Blot module, Life Technologies
TM
, 
USA) as Figure 15 demonstrates, and placed in the transfer chamber (XCell 
SureLock
TM
 Mini-Cell). The gel tension wedge was locked and the inner chamber 
filled with blotting buffer. The surrounding chamber was filled with ice water to 
prevent temperature fluctuation in the system during the blotting reaction as this may 
interfere with the transfer of the proteins. The apparatus was placed on ice at 4
0
C and 
run at 400 mAmp for one hour on a Power Pac 300 (BioRad, USA). After 1 hour, the 
apparatus was dissembled, and the membrane was transferred to a chamber for 
blocking. 
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Figure 15. The blotting chamber. The order of Pads, Whatman, Gels and membranes placed in the 
blotting chamber where the proteins on the gel are electro transferred to a polyvinylidene difluoride 
(PVDF) membrane (adapted from (106)).  
 
Step 3: Blocking the membrane  
 
To membranes were “blocked” to avoid unspecific binding of primary antibody to 
unoccupied spaces on the PVDF membrane, thereby preventing high background 
when developing the membrane. 10 mL of the appropriate blocking solution was 
added to the membrane and it was incubated at room temperature for 1 hour on a See-
saw Rocker (SSL4, Stuart®, USA and UK). The blocking solution constituted of 5 % 
Bovine Serum Albumin (BSA) (SIGMA-ADLRICH, USA) or 5 % nonfat dried milk 
in Tris-Buffered Saline and Tween 20 (TBST) consisting of 0.15 M NaCl, 10mM 
UltraPure™ TRIS-HCl (Life TechnologiesTM, USA) and 0.5 % Tween 20 (Merck, 
Germany) in distilled H20. All blocking solutions are listed in Table 2.  
 
TBST was not used when evaluating the B7-H3 protein levels, instead a buffer 
containing 0.5 % Tween in PBS to a total volume of 500 mL was used to prepare the 
blocking buffer and all subsequent solutions with primary and secondary antibody. 
Furthermore, this buffer was applied at all washing steps of the B7-H3 membrane. 
 
Step 4: Incubation with primary and secondary antibody 
 
To visualize the protein band immobilized on the membrane, the membranes were 
incubated with a primary antibody specific for the protein of interest, following 
incubation with an enzyme-coupled secondary antibody which detects the primary 
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antibody (Figure 13 E), F) and G)). The primary antibody was diluted in 5 % BSA in 
TBST or 5 % nonfat dried milk in TBST, and at dilutions recommended by the 
manufacturer. An overview of primary antibodies, dilution factor and solutions is 
presented in Table 2. The membranes were incubated overnight at 4°C under careful 
agitation on a Platform Rocker (Bibby Stuart STR6, USA and UK).   
 
Table 2. The antibodies used in the Western blot analysis. All antibodies utilized in present thesis 
are listed here. All primary and secondary antibody dilutions were prepared in TBST, apart from the 
B7-H3 antibody where both primary and secondary antibody dilutions were prepared in 0.5 % Tween 
in PBS (for manufacturer see Appendix B).  
Antibodies 
(Ab) 
Molecular 
weight 
(kDa) 
dilution of 
primary Ab 
Secondary Ab 
and dilution 
Antibody 
dilutants and 
blocking buffer 
Akt 60 1:1000 Rabbit (1:2000) 5 % BSA 
Phospho-Akt (Thr308) 60 1:1000 Rabbit (1:2000) 5 % BSA 
Phospho-Akt (ser473) 60 1:1000 Mouse (1:5000) 5 % Milk 
Phospho-Bad (ser112) 23 1:2000 Mouse (1:5000) 5 % BSA 
Phospho-GSK-3β 
(ser9) 
46 1:1000 Rabbit (1:2000) 5 % BSA 
Phospho-mTOR 
(Ser2448) 
289 1:1000 Rabbit (1:2000) 5 % BSA 
Phospho-PDK1 
(Ser241) 
58-68 1:1000 Rabbit (1:2000) 5 % BSA 
Phospho-elF4E 25 1:1000 Rabbit (1:2000) 5 % BSA 
Phospho-p70S6K 
(Thr389) 
70.85 1:1000 Mouse (1:5000) 5 % Milk 
α-tubulin 55 1:5000 Mouse (1:5000) 5%  Milk 
β-actin ~ 42 1:1000 Goat (1:2000) 5%  Milk 
Human B7-H3 ~100 1:1000 Goat (1:2000) 5%  Milk 
 
The subsequent day the membranes were washed three times in TBST for 15 minutes 
following incubation with the appropriate secondary horseradish peroxidase (HRP)-
coupled antibody. The secondary antibody was diluted in 5 % non fat dried milk or 
5% BSA in TBST for 1 hour at room temperature. The washing steps remove any 
remaining antibodies, and thus prevent unspecific binding. After incubation with the 
secondary antibody, the membranes were washed three times for 15 minutes in TBST. 
All washing steps were performed under gentle agitation on a See-saw Rocker (SSL4, 
Stuart®, USA) at room temperature.  
 
β-actin and α-tubulin were used to control protein loading and transfer differences on 
all blots.  
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Step 5: Protein imaging using chemiluminescense 
 
The secondary antibodies were coupled with a HRP-enzyme.  The Supersignal
®
 west 
dura Extended duration substrate (Thermo Scientific, USA) is a luminol-based 
enchanced chemiluminescense (ECL) HRP substrate which is used to detect HRP-
enzyme activity, and provides a chemoluminescent signal that is stable for several 
hours and can be detected on a chemiluminescense imager (107). The two HRP 
substrate components were mixed at a one to one ratio to prepare the substrate 
working solution, and the blots were subsequently incubated with the solution for 5 
minutes. Excess reagent was drained from the blots, and they were covered with a 
plastic sheet and imaged in a G-BOX chemi (Syngene, USA) using the Syngene 
Genesnap software (Figure 13 H). The exposure time varied from 20 seconds to 10 
minutes to find the optimal image.   
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3. Results 
3.1 Optimization of cell lines 
 
Prior to the drug screening procedure the breast cancer cell lines MDA-MB-435 and 
MDA-MB-231 variants, shB7-H3 (silenced for the expression of the B7-H3 protein) 
and vector control cells TR33 (expressing the protein) were optimized for growth in 
384 well plates for five days. The cells were lysed at day five by adding CTG, and 
luminescence was measured to quantify cell viability. The level of luminescence was 
plotted against increasing cell number (Figure 16). The optimal cell numbers are 
presented in Table 3. 
 
 
Figure 16. Growth curves of MDA-MB-435 and MDA-MB-231 cell variants. The X-axis presents 
the number of cells per well, whereas the Y-axis shows the measured luminescence levels. Each data 
point is an average of seven replicas. The TR33 vector control cells express the B7-H3 protein, 
whereas the protein is silenced in the shB7-H3 cells.  
 
Table 3. The number of cells chosen for drug screening procedure in 384 well plates.  
Cell line Cell line variant Cell number 
per well 
MDA-MB-435 TR33 500 
shB7-H3 650 
MDA-MB-231 TR33 750 
shB7-H3 900 
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3.2 Drug screening of breast cancer cells  
 
The sensitivity of the MDA-MB-435 and MDA-MB-231 shB7-H3 cells were 
compared to the TR33 cells in order to study the putative effect of knockdown of the 
B7-H3 protein on drug response. 
 
The cells were plated at their optimal numbers (Table 3) in 384 well plates containing 
22 drugs at different concentrations printed in duplicate (Medical Biotechnology 
VTT, Finland) (Table 1). After 5 days of incubation cell viability was measured to 
evaluate the drug response. The drug screening was performed twice for each cell line 
variant, and the reproducibility of the duplicate screens was evaluated with respect to 
their correlation (Figure 17). A high correlation, ranging from 0.87 - 0.91, showed 
that the replicate screens were similar and thus biologically representative. 
 
 
Figure 17. Scatter plots of two independent drug screening experiments for each cell line; MDA-
MB-435 (shB7-H3 and TR33) and MDA-MB-231 (shB7-H3 and TR33). Satisfactory correlation 
between duplicate drug screens was observed. All data was normalized before the correlation was 
examined.  
 
The cell lines were considered to be responsive to drugs that induced ≥ 20 % growth 
inhibition. This cutoff value was based on long-term experience with drug screening 
in 384 well plates from our collaborators in Finland. The percentage response of each 
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cell variant at the highest drug concentration is shown in Table 4 where a high 
response indicates high drug efficacy. 
 
Several of the drugs had an effect on both MDA-MB-435 and MDA-MB-231; 
Bortezomib, Doxorubicin Hydrochloride and Radicol induced the highest response. 
These are inhibitors of the proteasome, topoisomerase 2 and Hsp90, respectively. 
Furthermore, several drugs targeting proteins in the PI3K/Akt pathway had a good 
response and induced over 20 % growth inhibition. In general, the drugs targeting 
different receptors were non-responsive in all cell line variants, with the exception of 
BIBW2992 and Lapatinib targeting the HER2 and EGFR (Table 4). 
 
Table 4. The response (percentage) of each cell line variants upon exposure to the highest 
concentration of each drug. A drug response of 97 % indicates that only 3 % of cells were left in the 
well when compared to 100 % growth. The compounds, their targets, and the percentage response upon 
exposure to the highest drug concentration are shown. Blue colors indicate that the cells were non-
responsive (per definition, < 20 % growth inhibition was used as a cutoff value as non-responsive), 
orange indicates 20 - 60 % response of the cell lines and yellow indicates drugs that induced > 80 % 
response in the cells.  
Compound Site of action 
Response at the highest drug concentration 
(percentage) 
MDA-MB-435 MDA-MB-231 
TR33 shB7-H3 TR33 shB7-H3 
Bortezomib Proteasome 97 97 96 96 
Doxorubicin 
Hydrochloride 
Topoisomerase 
2 
96 95 96 94 
Radicicol Hsp90 84 73 87 85 
BIBW2992 EGFR + HER2 67 68 51 58 
API-2 Akt/PKB 31 45 50 63 
Temsirolimus mTOR1 47 48 47 49 
Everolimus mTOR1 39 36 41 42 
PI 103 Hydrochloride PI3K/mTOR 24 21 32 35 
Wortmannin PI3K 17 22 28 35 
PD 184352 MEK/ERK 25 31 28 11 
4-hydroxytamoxifen ER 19 22 24 29 
Lapatinib EGFR + HER2 27 20 22 25 
Akt 1/2  kinase inhibitor Akt/PKB 5 8 23 21 
Trastuzumab HER2 21 18 20 22 
UO126 MEK/ERK 4 0 25 18 
CI-1033 Pan-ErbB 6 5 11 14 
PD153035 Hydrochloride EGFR 6 4 14 10 
Symansis CP-724714 HER2 10 9 11 12 
Bevacizumab VEGFR 3 7 9 7 
Gefitinib EGFR 4 3 8 8 
AAL-993 VEGFR 4 3 8 8 
AG 538 IGFR -2 1 3 6 
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The differences in drug response between the shB7-H3 cells and TR33cells at all drug 
concentrations in each cell line for the drugs that induced ≥ 20 % growth inhibition 
were investigated using a Student’s t-test. 
 
3.2.1 Drug response in MDA-MB-435 cell variants 
 
The drug screening identified four different compounds that had significantly 
different efficacy in the MDA-MB-435 shB7-H3 cells compared to the TR33 cells. 
These drugs were API-2, an AKT inhibitor, Bortezomib, an inhibitor of the 
proteasome, Radicicol, an Hsp90 inhibitor and Doxorubicin hydrochloride, a 
Topoisomerase 2 inhibitor. Figure 18 presents the growth response curves of these 
drugs. 
 
API-2 treatment showed a better efficacy in the shB7-H3 variants at the three highest 
concentrations; 200 nM (p = 0.045371), 2 µM (p = 0.00166) and 20 µM (p = 
0.00502). A good effect of Bortezomib was seen in both cell variants, however at 52 
nM (p = 0.046136) the efficacy was significantly better in the shB7-H3 cells. 
However, exposure to Radicicol resulted in a significantly better response in the TR33 
cells at 2 µM (p = 0.000467) and 20 µM (p = 0.032435). Doxorubicin hydrochloride 
also had a better efficacy in the TR33 cells at 200 nM (p = 0.003653).  
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A) B) 
               
 
C)               D) 
      
Figure 18. Growth response curves of the drugs with significant different efficacy in the MDA-
MB-435 cell variants. The y-axis represents the relative response (%) versus the logarithmic 
concentration of the drugs on the x-axis. Green circles represent the response of the B7-H3 expressing 
cells and the purple squares show the response of the B7-H3 knockdown cells, shB7-H3. The figures 
show the growth inhibition upon treatment with A) Radicicol (*p = 0.000467, ** = 0.032435), B) 
Doxorubicin hydrochloride (*p = 0.003653), C) API-2 (*p = 0.045371, ** = 0.00166, *** = 0.00502) 
and D) Bortezomib (*p = 0.046136). All data has been normalized.  
 
3.2.2 Drug response in MDA-MB-231 cell variants 
 
Five different drugs were identified as having a significantly different efficacy in the 
MDA-MB-231 shB7-H3 cells compared to the TR33 cells. These drugs were API-2, 
Everolimus, an mTOR inhibitor, Doxorubicin hydrochloride and the MEK/ERK 
inhibitors UO126 and PD184253. The growth inhibition curves are shown in Figure 
19.  
 
Both API-2 and Everolimus showed a consistently better efficacy in the B7-H3 
knockdown cells. API-2 had a better efficacy at 200 nM (p = 0.007852), 2 µM (p = 
0.002208) and 20 µM (p = 0.000030) whereas Everolimus had a better efficacy at 20 
~ 48 ~ 
 
nM (p = 0.019225), 200 nM (p = 0.001515) and 2 µM (p = 0.014489). Doxorubicin 
hydrochloride had a high effectiveness in both cell lines, but a better response in the 
B7-H3 knockdown cells at 200 nM (p = 0.000309) was observed. Although the small 
molecule inhibitors PD184352 and UO126 had minimal effect in any of the cell 
variants, the highest drug concentrations, 8µM (p = 0.001285) and 20 µM (p = 
0.032548) respectively, showed a more pronounced effect in the TR33 cells.  
 
A)  B) 
 
C)       D) 
         
E)      
 
Figure 19. Growth response curves of drugs with significant different efficacy in the MDA-MB-
231 cell variants. The y-axis represents the relative response (%) versus the logarithmic concentration 
of the drugs on the x-axis. Green circles represent the response of the B7-H3 expressing cells and the 
purple squares show the response of the B7-H3 knockdown cells. The graphs show the growth 
response upon treatment with the anti-cancer drugs A) UO126 (*p = 0.032548), B) PD184352 (*p = 
0.001285), C) Everolimus (*p = 0.019225, ** = 0.001515, *** = 0.014489), D) Doxorubicin 
hydrochloride (*p = 0.000309) and E) API-2 (*p = 0.007852, ** = 0.002208, *** = 0.000030). All data 
has been normalized.  
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3.2.3 The half maximal effective concentration (EC50) 
 
The EC50 is defined as the concentration of drug that shows a response halfway 
between the baseline and the maximum response of a dose-response curve (108). The 
EC50 values were determined from the dose-response curves, which usually follow a 
sigmoid shape (S-shape). If this shape were not achieved, for example due to lack of 
high enough drug concentrations to reach a maximum response, the calculation of an 
EC50 value would be ambiguous and therefore not calculated. The EC50 values of 
drugs with significant difference in the cell variants are presented in Table 5. 
 
Table 5. The EC50 Values of MDA-MB-435 and MDA-MB-231 cell variants. N/A = Not analyzed 
because a maximum response was not reached. A square with a dash (-) indicate that there was no 
significantly different efficacy between the cell line variants, and EC50 values was thus not calculated. 
 
Cell line 
EC50 Values (µM) 
MDA-MB-435 MDA-MB-231 
Variant TR33 shB7-H3 TR33 shB7-H3 
API-2 2.61 1.51 3.03 1.06 
Doxorubicin Hyrdochloride 0.53 0.97 0.60 0.47 
Radicicol 1.65 2.94 - - 
Bortezomib 0.11 0.08 - - 
Everolimus - - 0.02 0.01 
UO126 - - N/A N/A 
PD184253 - - N/A N/A 
 
 
3.3 Confirmation of B7-H3 silencing in MDA-MB-435 and 
MDA-MB-231 cell variants 
 
Western blot analysis showed the shB7-H3 cells had a very low expression of the B7-
H3 protein compared to the TR33 cells in both cell lines tested, which demonstrated 
that the model system was adequate (Figure 20). 
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Figure 20. Western blot analysis confirming knockdown of the B7-H3 protein: Western blot 
analysis of the B7-H3 expression in MDA-MB-231 and MDA-MB-435 cell variants (shB7-H3 and 
TR33). The shB7-H3 cells showed a low expression of the protein compared to their TR33 
counterparts. α-tubulin was used as loading control (The blot is representative of three independent 
experiments).  
 
3.4 Western blot analysis of target proteins in the 
PI3K/AKT pathway 
 
The drug screening revealed drugs that showed a consistently better response in the 
shB7-H3 cells. API-2 had a better effect in the shB7-H3 cells of both MDA-MB-231 
and MDA-MB-435, whereas for Everolimus this was only shown for MDA-MB-231 
shB7-H3 cells. These small molecule inhibitors were chosen for further investigation 
of the molecular mechanisms behind the difference in response. 
 
The cells were exposed to these drugs for 0 hours, 0.5 hours and 2 hours before the 
phosphorylation levels of target proteins were examined. MDA-MB-435 cell variants 
were treated with 20 µM API-2, whereas the MDA-MB-231 cell variants were treated 
with either 2 µM API-2 or 200 nM Everolimus. These concentrations were achieved 
from the drug screening at concentrations with the most pronounced difference 
between the cell line variants. API-2 is a selective Akt inhibitor whereas Everolimus 
inhibits mTOR. Therefore we chose to examine the regulation of several proteins in 
the PI3K/Akt-mTOR pathway.  
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3.4.1 MDA-MB-435 cells treated with API-2 (20 µM) 
 
The phosphorylation levels of elF-4E, Akt (ser473), mTOR and p70S6 kinase 
(p70S6K) were investigated in MDA-MB-435 cell variants treated with API-2 
(20µM), but no differences were found between the cell variants (data not shown).  
 
3.4.2 MDA-MB-231 cells treated with API-2 (2µM) 
 
MDA-MB-231 shB7-H3 cells treated with API-2 showed a reduction in Akt 
phosphorylated at serine 473 (ser473). p-Akt is the active form of Akt where it can 
subsequently phosphorylate and regulate downstream targets (Figure 19). The 
phosphorylation of mTOR (activate mTOR) did not change at any time point after 
treatment with API-2 (Figure 21). However, a dramatic reduction in the 
phosphorylation level of a downstream target of mTOR, the p70S6K (active when 
phosphorylated), was seen in the B7-H3 knockdown cell variants (Figure 22).  
 
In addition, the phosphorylation levels of several other central proteins in this 
pathway, elF4E, GSK-3β and BAD, were also studied, however no differences 
between the cell variants were observed (data not shown). 
 
Figure 21. The effect of API-2 exposure (2µM) on phospho-Akt levels in MDA-MB-231 cell 
variants. The cell variants were exposed for 0 hours, 0.5 hours and 2 hours and protein activity was 
evaluated by comparing the cells at each time interval as indicated by the stippled box. The levels of 
phosphorylated Akt (p-Akt (Ser473)) decreased over time in the B7-H3 knockdown cells. Total Akt 
and β-actin were used as loading controls (The blot is representative of two independent experiments).  
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Figure 22. The effect of API-2 exposure (2µM) on phospho-mTOR and phospho-p70S6K levels in 
MDA-MB-231 cell variants. Cell variants were exposed for drugs for 0 hours, 0.5 hours and 2 hours. 
The blot showed no difference in p-mTOR levels, but a markedly decrease in phosphorylation level of 
the downstream target of mTOR, p70S6K. This was only observed in the B7-H3 knockdown variants, 
but not in the B7H3 expressing variants. β-actin were used as loading controls (The blot is 
representative of two independent experiments).  
 
3.4.3 MDA-MB-231 cells treated with Everolimus (200 nM) 
 
The MDA-MB-231 cells treated with Everolimus showed a reduction in p-p70S6K 
levels in B7-H3 silenced cells, but not in the p-mTOR levels of either cell variants 
(Figure 23). Interestingly, the levels of phosphorylated Akt (ser473) showed a 
dramatic increase in both cell variants upon treatment with Everolimus, however, this 
was less pronounced in the B7-H3 knockdown cells (Figure 24).  
 
The levels of p-elF4E were also investigated, but showed no difference between the 
cell variants (data not shown). 
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Figure 23. The levels of p-mTOR and p-p70S6K upon exposure to 200 nM Everolimus in MDA-
MB-231 cell variants. The levels of p-mTOR did not change during exposure to the drug. A marked 
decrease in the phosphorylation levels of p70S6K was observed in the B7-H3 knockdown variants. α-
tubulin was used as a loading control (The blot is representative of two independent experiments).  
 
 
 
Figure 24. The levels of p-Akt upon exposure of 200 nM Everolimus in MDA-MB-231 cell 
variants. The levels of p-Akt (ser473) increased with time after drug exposure in both cell variants, 
and slightly less in the B7-H3 knockdown cells. Total Akt and β-actin were used as loading controls 
(The blot is representative of two independent experiments).  
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4. Discussion 
 
4.1 Methodological considerations 
4.1.1 In Vitro cell cultures 
 
Cultured human cancer cell lines are valuable tools for functional studies in cancer as 
they have many of the same recurrent genomic and transcriptional characteristics as 
tumors (109). Therefore they are good models for experiments that are not possible to 
conduct in humans, both due to practical and ethical reasons. Cell lines are easily 
accessible, propagated and maintained, whereas primary tumors are of limited access. 
Furthermore, cell lines present homogenous cell populations, while primary tumors 
are heterogeneous with stroma consisting of infiltrating lymphocytes and other cell 
types, making the actual tumor cell percentage low. This may be a limitation of 
several models. However, cell lines can be manipulated by establishing specific 
phenotypes, like the B7-H3 knockdown model in the present thesis, making it 
possible to study both function and the impact of specific molecules on malignant 
processes. Moreover, in vitro models have also been shown to be predictive of in vivo 
drug response, emphasizing their relevance in cancer research (110).  
 
The fact that cancer cell lines are genomically unstable makes it important to avoid 
long term culturing and high confluence levels, as this may influence the genetic 
composition, and thus effect the phenotypic properties, of the cells (111). When the 
cells become too confluent the lack of nutrition, space and the accumulation of waste 
might influence the gene expression. For example by for upregulating stress related 
genes and activating genes to resist apoptosis. By standardizing the culturing 
conditions using optimal culture medium, maintaining the cells at low passage 
numbers and at a confluence level of approximately 80 %, we tried to minimize the 
risk of genetic drift that might influence the results. In order to achieve reproducible 
and quantifiable results cells must also be propagated under well-defined 
experimental conditions (112). Moreover, established sterile techniques were used to 
prevent contaminations, and the cell lines were routinely checked for mycoplasma 
infections. Another aspect of in vitro cell cultures is the risk of cross-contaminations 
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(113). As the cells are used in experimental models as surrogates for their tissue of 
origin, their identity is important for the validation of data. The MDA-MB-435 and 
MDA-MB-231 cell lines were purchased from the American Type Culture Collection 
(ATCC), and have previously been authenticated in our laboratory (101).  
 
It is important to take into consideration that cells are dynamic, living organisms that 
might for instance fluctuate in growth rate when conducting in vitro experiments. This 
makes it important to perform experiments several times and obtain reproducible 
results, which assures that any differences or effects observed are general, and not due 
to random events.  
 
Although cancer cell lines are useful tools, they are only experimental models of 
human cancer, and thus have their limitations in entirely recapitulating the disease in 
humans. Breast cancer is thought to develop due to intrinsic properties of the tumor 
cells, as well as through interaction with cells and signaling molecules present in the 
microenvironment, and this crosstalk is also important in the process of metastasis 
(114). Clearly, the complex microenvironment is not recaptured in the in vitro setting. 
The work in the present thesis was performed in two dimensional (2D) cultures, 
which is a well-established procedure in our laboratory. Cells can also be cultured 
three dimensionally (3D) which presents an opportunity to assay cell behavior in a 
system that more closely resembles the in vivo setting (115;116). However, the work 
with 3D culturing is more laborious, and would require another experimental setup. 
The use of a 3D culturing system or xenografts could be used to stratify the results 
from the present experiments, as these experimental models provide a closer 
similarity to the disease in humans (112;115). In general, there are less ethical and 
practical considerations by the use of in vitro cell culturing opposed to in vivo, and 
although there use cannot fully replace xenografts, cell lines serve as valuable first 
line experimental models.  
 
4.1.2 The origin of cell line MDA-MB-435 
 
The origin of the cell line MDA-MB-435, used in our experiments, has been debated. 
It was initially derived from a patient with ductal adenocarcinoma, and was thus 
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identified as a breast cancer cell line (117). However, microarray derived data have 
indicated that the gene expression pattern of the cell line resembles that of human 
melanoma cells, which was confirmed in other studies (118;119). In contrast to these 
findings, there are also indications of the mammary epithelial origin of this cell line 
(120). The identification of co-expression of mammary epithelial cell and melanocyte 
markers has postulated that this is due to lineage infidelity (121). This has further 
been supported by additional studies suggesting that the MDA-MB-435 is indeed a 
breast cancer cell (122;123).  
 
The aim of this study was to investigate the putative effect of the B7-H3 protein on 
anti-cancer drug resistance, which is a general feature of cancer cells. Despite the 
controversy regarding the origin of the MDA-MB-435 cell line, we chose to use this 
cell line as a model to study the role of B7-H3 in resistance. The cell line was already 
an established B7-H3 knockdown model utilized and verified in our laboratory 
(101;102). Moreover, another breast cancer cell line was included in our experiments 
and strengthens our findings and justifies the choice of models. Our result should, 
however, be up scaled and stratified in a larger sample size in order to investigate if 
the function of B7-H3 is a general phenomenon in anti-cancer drug resistance.  
  
4.1.3 Drug screening of breast cancer cell lines 
 
Cancer cells have a high degree of genomic diversity that contributes to their drug 
sensitivity. High throughput drug screening has been used to systematically identify 
genomic markers of drug sensitivity in cancer cells, and also as a tool to link genetic 
composition to drug response (124;125). Through drug screening, multiple cancerous 
processes can be investigated simultaneously, making the technique effective in the 
search for novel treatment strategies. In the present thesis we refer to a small scale 
drug screening where B7-H3 silenced and B7-H3 expressing cell lines were screened 
with 22 different compounds. This allowed the investigation of possible differences in 
drug efficacy between B7-H3 silenced and B7-H3 expressing cells, and thereby the 
investigation of the function of the B7-H3 protein in drug response.  
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The use of 384 well formats requires small amounts of drugs and other reagents, 
which makes it both cost-efficient and safer compared to experiments in larger scale, 
in example in 96 well plates. The small volumes of cells, drugs and other reagents that 
were utilized require accurate pipetting. A robot was used to print the drugs on the 
plates, and a reagent dispenser was used to add cells and CTG to the wells, making 
the procedure more demanding with regards to machinery. However, this accuracy in 
printing and dispensing of such small volumes is not possible to achieve manually, 
thus increasing the reliability of the results. The growth of cells in small volumes is 
more challenging due to the constriction it imposes on the microenvironment and 
nutrient medium, and evaporation may therefore influence cell growth. Although cells 
that grow in vitro lack a microenvironment compared to the in vivo setting, cells 
strongly rely on interaction with other cells in the culture through signaling molecules 
and cell-to-cell contact to grow and thrive. Thus, to achieve reliable results, the cells 
were carefully optimized to obtain the best cell seeding number for the 384 well 
formats for five day long experiments. This was chosen from the growth curves 
obtained in the optimization procedure, at the steepest point before the curve flattens. 
At this point the cells are in their logarithmic phase of growth, which means they are 
highly proliferative and they have enough space to divide. When the number of cells 
becomes too high and the wells are confluent, the limitation of nutrients and space 
will affect the cell viability, and cells will die off or cease growing. In addition, the 
confluence levels in the 384 well plates were observed in the microscope at the 
endpoint of each drug screen (confluence levels of approximately 70-80 % in the 
controls were regarded as satisfactory).    
 
An edge-effect could be observed as a tendency of reduced cell growth at the outer 
wells of the plates (Figure 24). This phenomenon has previously been observed by our 
collaborators at Medical Biotechnology VTT in Finland, and was taken into 
consideration in the design of the plate. Thus, there were no drugs in the outer wells. 
However, the plate-specific growth pattern made the outer wells inappropriate as 
controls. The lowest concentration of drugs (two middle rows, Figure 25) was 
therefore used as a reference of 100 % growth. Although the use of drug-free controls 
in theory would be beneficial, no growth inhibition was observed at the lowest 
concentrations, and therefore they were considered adequate controls.  
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The drugs were printed in different dilutions which made it possible to make growth 
inhibition curves and calculate EC50 values directly from the curves. Different levels 
of luminescence could be observed for each cell line, however all data was 
normalized against 100 % growth before the cell lines were compared thus correcting 
for differences in luminescence levels between the different screenings.  
 
 
Figure 25. A heatmap of a drug screening plate. The colors represent levels of luminescence which 
reflects drug effect. Low levels (Blue) indicate low growth, yellow represents intermediate levels and 
orange/red represents high levels of luminescence and high cell viability. A tendency towards better 
growth in the middle, and less growth towards the edges was observed.  
 
In our experiment, cell viability was used as an endpoint to measure the drug 
response. There are several other methods of measuring drug efficacy, for example by 
measuring the levels of apoptotic proteins. However, many of the drugs that were 
utilized are small molecule inhibitors which in many cases reduce cell growth 
(cytostatic) and do not directly induce apoptosis (cytotoxic), and cell viability was 
therefore considered to be a more suitable endpoint in this assay.  
 
4.1.4 Western blot analysis of proteins 
 
Protein activation levels were assayed by Western blot analysis. There are many 
antibodies available targeting numerous proteins, and at specific phosphorylation 
sites, allowing the investigation of both total protein levels in cells, and the degree of 
phosphorylation and thus the activity. However, the investigation of phosphorylated 
proteins can be cumbersome. As protein activity by phosphorylation is a dynamic 
process, precautions must be taken to prevent the dephosphorylation of proteins in the 
samples, and the harvesting of cells is an essential element in this process. Proteins 
may be altered with respect to phosphorylation when harvested enzymatically, thus 
other harvest methods are recommended when blotting of phospho-proteins (126). A 
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broad spectrum of phosphatase and protease inhibitors were added to the buffer when 
obtaining and lysing the cell pellets. In addition, the cells were kept on ice and 
detached by using a cellscrape to minimize dephosphorylation and degradation of 
proteins. 
 
Optimizing the procedure with regards to cell lysing, as described above, sample 
amount, buffer conditions, dilutions of primary and secondary antibodies, and 
blocking reagent, may be necessary to obtain successful results. To achieve good 
results established Western blot analysis methods were utilized, either as provided by 
the manufacturer or established in our laboratory.  
 
Cross reactivity of primary and secondary antibody is another challenge in Western 
blotting, which means that an antibody may recognize and bind other proteins than it 
initially is targeted for on the membrane. This can occur if the proteins share the same 
epitope recognized by the antibody, and may produce high background, unclear bands 
or multiple bands. The blocking solution and the concentration of antibodies used are 
often of importance with regard to this, and all blocking solutions and antibody 
dilutions was prepared as recommended by the manufacturer.   
 
As described above, there are multiple challenges when performing Western blot 
analysis, which we also encountered in the detection of phosphorylated Akt at 
Threonine 308. As both phosphorylation of Akt at Thr308 and Ser473 is required for 
its full activation, we wanted to investigate both residues, since this would best reflect 
the activity of Akt. However, we were not able to detect any bands with our antibody. 
This might be due a number of technical issues, for example old antibody or the need 
of careful optimization. However, the investigation of downstream molecules of Akt 
is also a good way to assay protein activity. Thus, the detection of regulation of 
proteins downstream of Akt was regarded as indicative of reduced kinase activity. 
Futhermore, the phosphorylation of Akt at Ser473 has been used to detect activated 
Akt in a wide panel of studies, and also as a demonstration of prognostic significance 
of Akt activation (127). This, together with an observed corresponding decrease in 
phospho-Akt (Ser473), further strengthens the indication of an observed reduction in 
activity of the protein. 
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The cells were treated with different concentrations of the drugs API-2 and 
Everolimus before Western blot analysis was performed in order to identify any 
differences in protein regulations. The different drug concentrations were selected 
based on the growth inhibition curves at concentrations that showed the largest 
difference between the shB7-H3 and TR33 cells. At these points, it was postulated 
that the differences in regulation levels would be more pronounced.  
 
In the initial experimental design the cells were incubated with drugs for the same 
time as the duration (five days) of the drug screening before protein activation levels 
were analyzed. However, no consistent results were found. API-2 and Everolimus 
have in previous studies been shown to induce an effect in vitro after 0.5 hours 
(128;129). Therefore, a new experimental design was chosen in order to better 
evaluate the immediate difference in response between the B7-H3 knockdown and 
B7-H3 expressing cells. We were interested in investigating the differences in 
response with regards to activity levels of proteins in the PI3K/Akt pathway, and not 
the total protein levels. The regulations of signaling molecules are rapid and dynamic 
and thus to better investigate the response with regards to protein phosphorylation 
levels upon drug exposure, we chose to treat cells for 0 hours (as a reference to no 
treatments), 0.5 hours and 2 hours. In general, all blots should be performed three 
times to ensure that the results observed are biologically reproducible, and not biased 
by other factors, such as timing, cell cycle or experimental design.  All Western blot 
results represented in this thesis have been performed twice on biological replicates 
(cells seeded and treated in separate experiment), and hence they must thus be 
considered as preliminary results. However, the consistency in the Western blot 
analysis is promising, and further analysis will be performed to validate the results. 
 
4.2 Biological considerations 
 
In the present study it was shown that knockdown of the B7-H3 protein increased the 
sensitivity of two triple negative metastatic breast cancer cell lines, MDA-MB-231 
and MDA-MB-435 to API-2, a selective Akt inhibitor. MDA-MB-231 B7-H3 
silenced cells were also sensitized to Everolimus, an mTOR inhibitor.  This was 
shown to be, at least partially, due to B7-H3 associated regulation of targets in the 
PI3K/Akt pathway in the MDA-MB-231 cells. More specifically the phosphorylation 
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of molecules, such as p70S6K and AKT, was decreased by B7-H3 silencing thus 
abrogating downstream protein translation and cell growth.    
 
B7-H3 is an immunoregulatory protein which has previously been shown to have both 
inhibitory and stimulatory functions with regards to T-cell activity. Its expression has 
been associated with poor prognosis and advanced disease in a number of different 
tumor types, including in breast cancer (89;97;98). Regardless of its regulatory 
immunological functions, novel non-immunological roles of this protein in tumor 
biology have been identified. Chen et al demonstrated that B7-H3 expression 
correlated with increased migration and invasion in vitro (100), and this has also been 
confirmed by in vivo studies where a decreased metastatic potential was seen in nude 
mice injected with B7-H3 silenced cancer cells (101). A connection between the 
expression of B7-H3 and the resistance to the chemotherapeutic drug Paclitaxel in 
breast cancer has recently been demonstrated, where B7-H3 protein knockdown 
sensitized the cells to this compound both in vitro and in vivo (102).  This, together 
with evidence from the present thesis, where silencing of the B7-H3 protein increased 
the sensitivity of breast cancer cells to two small molecule inhibitors, may indicate a 
more general association between B7-H3 expression and resistance. Hence the B7-H3 
protein may be a putative prognostic and possible therapeutic marker. 
 
The growing understanding of cancer cell biology has identified several pathways and 
molecules which are frequently highly expressed in cancer. These pathways are 
necessary for the growth and/or survival of certain cancers, which has fuelled the 
development of targeted therapy specifically inhibiting components of signaling 
pathways (130). Targeted therapy is different from conventional therapy in its 
specificity towards particular features of the tumor cells. Tamoxifen, Trastuzumab 
and Lapatinib are examples of such therapy that are currently used in the clinical 
setting against tumors overexpressing the estrogen and the HER2 receptor, 
respectively. Targeted therapy consists of antibodies, like Trastuzumab, but also a 
group of compounds called small molecule inhibitors, which inhibits components in 
intracellular signaling pathways frequently activated in human malignancies. This 
therapeutic approach presents a step towards a more personalized treatment strategy 
where the therapy could be tailored based on the genes and proteins that are 
deregulated in an individual patient’s tumor. This approach has thus the potential to 
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increase the efficacy of cancer treatment and reduce the adverse side effects of 
conventional therapy (130). 
 
Several of the compounds used in this study are categorized as targeted therapy. They 
included anti-cancer drugs targeting the ErbB receptor family like the EGRF, HER2 
and HER4 receptor, but also drugs targeting the IGFR2, ER and VEGFR receptors. 
These receptors are widely implicated in many human malignancies, including breast 
cancer. For example, the ErbB family is frequently upregulated in breast cancer, and 
is one of the main signaling pathways where targeted therapy is being developed 
(130;131). Moreover, small molecules inhibiting PI3K, Akt, mTOR and MEK/ERK, 
which act downstream of these receptors (except the ER receptor) were included in 
the drug panel, in addition to three anti-cancer drugs targeting the proteasome, HSP90 
and topoisomerase II, respectively. The PI3K/Akt pathway has been implicated in 
chemoresistance in breast cancer cells, and compounds targeting this signaling 
pathway were therefore of interest when investigating the putative impact of B7-H3 
on anti-cancer drug resistance (86). Several of these are new substances and their 
clinical significance remains to be established, whereas some are already approved in 
the treatment of breast cancer, such as Lapatinib and Trastuzumab, or other types of 
cancers, such as Temsirolimus, Everolimus.  
 
In general, targeted therapy have shown limited effect as single agents, and are often 
used in combinations with other targeted agents or conventional therapy, where they 
have shown to increase the treatment efficacy. For example, the combination of 
Paclitaxel with the dual HER2/EGFR tyrosine kinase inhibitor Trastuzumab and the 
HER2 inhibitor Lapatinib significantly improved the complete pathological response 
in women with HER2+ breast cancer as compared to any of the treatments in 
combination with Paclitaxel alone (132). In line with this combinatorial approach we 
wanted to investigate if the knockdown of the B7-H3 protein could be involved in 
regulating the response to any of the anti-cancer compounds used in the screen, and 
showed that knockdown of B7-H3 in combination with API-2 or Everolimus seemed 
to be more effective than administering the small molecules alone when cells 
overexpress B7-H3. The observed sensitization upon combinatorial inhibition 
emphasizes the complexity of cancer treatment and the potential of a combinatorial 
approach to improve patient outcome (127).  
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Several of the substances in the drug screening showed an effect on the cell lines as 
defined by the > 20 % cutoff level. The best responses were seen upon treatment with 
Bortezomib, Doxorubicin Hydrochloride and Radicol. The cell lines used in the 
present thesis are triple negative breast cancer, and are thus not expressing the ER, PR 
or HER2 receptors. However, the dual EGFR + HER2 inhibitor BIBW2992 had 
relatively good response in both cell lines, but in general the drugs targeting receptors 
showed a low response, and the majorities were considered non-responsive. As the 
aim of the drug screen was to investigate the effect of B7-H3 knockdown on drug 
response, the anti-cancer drugs that showed a continuously better effect in the B7-H3 
knockdown, as compared to the B7-H3 expressing cells, were chosen for further 
investigation of the underlying molecular mechanisms. The downregulation of B7-H3 
expression increased the effect of API-2 and Everolimus, which specifically inhibits 
targets in the PI3K/AKT pathway, AKT and mTOR respectively. In line with this we 
have previously observed that B7-H3 silenced breast cancer cells were more sensitive 
to the drug Paclitaxel by, at least partially, abrogating the Jak2/Stat3 signaling 
pathway (102). Thus our findings further confirm the ability of B7-H3 to modulate 
intracellular signaling.  
 
The PI3K/Akt pathway is constitutively active in many human cancers, including 
breast cancer (76). This has stimulated the development of many small molecule 
inhibitors targeting components in this pathway (127). Akt/Protein Kinase B 
Signaling Inhibitor-2 (API-2/Triciribine) is a highly selective Akt kinase inhibitor 
which inhibits the phosphorylation, activation and signaling of the three Akt isoforms; 
Akt1, Akt2 and Akt3. It was identified as a specific Akt inhibitor suppressing cell 
growth and inducing apoptosis preferentially in human cancers with constitutively 
active Akt signaling (128). So far, API-2 has been combined with standard 
chemotherapies or radiation in preclinical studies (127) . Everolimus (RAD001) is a 
rapamycin analogue that inhibits mTOR1 activity (rapaloge) (129). This is mediated 
through Everolimus binding to the FK506-binding protein-12 immunophilin (FKBP-
12), and this complex subsequently binds to a specific site near the catalytic site of 
mTOR and inhibits the phosphorylation of its downstream substrates through a poorly 
described mechanism (133). The drug is marketed as Affinitor (Novartis) and is 
~ 64 ~ 
 
approved for the treatment of advanced kidney cancer and recently also other cancers 
(Approved by the U.S Food and Drug Administration (FDA) (134)).  
 
To investigate whether we could relate the observed sensitization upon B7-H3 
knockdown to activity levels of proteins in the PI3K/Akt pathway we performed 
Western blot analysis. An overview of the target proteins and the pathway are 
illustrated in Figure 26. The MDA-MB-231 B7-H3 knockdown cells showed 
decreased levels of phosphorylated Akt (Ser473) compared to the B7-H3 expressing 
cells upon treatment with API-2. mTOR1 is a central  sensor of nutritional status and 
determines whether the cell should grow, and Akt signaling through mTOR1 plays an 
important role in the regulation of cell growth, proliferation and survival (130). 
Analysis of the phosphorylation levels of mTOR did not show any difference upon 
API-2 treatment. However, the downstream target of mTOR, the protein 70 S6 kinase 
(p70S6K), showed a dramatic reduction in activation level in B7-H3 silenced cells. 
p70S6K is a major stimulator of cell growth by promoting translation of ribosomal 
proteins and other transcriptional elements, and is activated by mTOR mediated 
phosphorylation (129). The observed decrease in phosphorylated p70S6K in the B7-
H3 knockdown cells thus might, in part, explain the increased sensitization in the 
shB7-H3 cells upon API-2 treatment. A reduction of the phosphorylation levels of 
p70S6K was also seen in the MDA-MB-231 B7-H3 knockdown cells treated with 
Everolimus, whereas no differences were observed in the phosphorylation levels of 
mTOR. P70S6K has also been indicated as a biomarker of mTOR inhibition (135), as 
rapaloges has been demonstrade to predominantly inhibit mTOR signaling trough 
p70S6K phosphorylation (129). This implies that there might be a B7-H3 induced 
regulation of proteins in this pathway, and that knocking down B7-H3 increased the 
sensitivity to either drug via the same mechanism.  
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Figure 26. A simplistic overview of the PI3K-Akt-mTOR1 signaling pathway. The activation of 
this pathway leads to protein synthesis, cell growth and proliferation. The inhibitory effect of API-2 
and Everolimus are indicated.  
 
Several studies have shown that mTOR inhibition has resulted in a compensatory 
upregulation of Akt, thus limiting the effect of drugs targeting mTOR. O’Reilly et al 
demonstrated that Everolimus treatment induced the expression of Insulin receptor 
substrate-1 (IRS-1) (a positive regulator of the PI3K/Akt pathway) and increased Akt 
activation in both cancer cell lines and patient tumors (136). In line with this, we 
observed an upregulation of p-Akt levels (Ser473) in both vector control and B7-H3 
silenced cells upon mTOR1 inhibition with Everolimus. This effect might be 
explained by the abrogation of a p70S6K dependent negative feedback loop that 
inhibits PI3K/Akt signaling. Hyperphosphorylated p70S6K inhibits IRS-1, an 
upstream activator of PI3K/Akt signaling, thus reducing Akt activity (137).  An 
inhibition of mTOR results in decreased phosphorylation of p70S6K, thus abrogating 
the negative feedback loop, resulting in increased Akt activity. This contradictory 
effect of mTOR inhibition on Akt activity, in addition to its predominant cytostatic 
effect, may explain the limited effect of mTOR1 inhibitors as single agents in cancer 
management. However, dual inhibition of mTOR1 and Akt could, in theory, reverse 
this effect. 
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Compensatory upregulation of oncogenic pathways is well known, and has been 
shown in several studies. For instance, it has been demonstrated that Akt inhibition 
induced signaling through the MAPK/ERK pathway (138). Limitations of targeted 
therapy as single agents can therefore be explained by the fact that cancer cells can 
have oncogenic pathway redundancy, where multiple pathways are able to sustain 
tumor growth and development. Moreover, many small molecule inhibitors, such as 
Temsirolimus and Everolimus, are primary cytostatic substances, meaning that they 
will suppress cell growth, but not necessarily induce apoptosis. The plasticity and the 
extensive crosstalk within cellular pathways emphasize that multiple, rather than 
single agent targeted therapy, probably is a more efficient approach (Figure 27). By 
inhibiting multiple signaling pathways simultaneously resistance induced by 
intracellular crosstalk and redundancy can be circumvented. Hence, the understanding 
of the underlying molecular mechanisms of drug response is crucial to rationally 
combine treatment to the individual tumor.   
 
 
Figure 27. Cellular signaling. Cell signaling is complex, and is not linear but consists of a complex 
network with crosstalk and regulation. The abrogation of one malignant pathway might therefore be 
insufficient to abrogate a malignant signaling pathway, here illustrated in green, emphasizing the 
combinatorial approach of drug design. Importantly, to be able to rational design treatment, the 
complexity of signaling cascades needs to be investigated further (Modified from (139)).   
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Together, our results imply that the sensitization observed in the B7-H3 silenced cells 
upon treatment with API-2 and Everolimus is, at least in part, mediated through 
abrogating the Akt-mTOR1-p70S6k pathway in the MDA-MB-231 cells, resulting in 
decreased cell growth and proliferation through inhibiting protein translation. 
However, the specific role of B7-H3 in this context needs to be investigated further. 
 
The genetic composition of the cell lines may also contribute to the drug response. 
The MDA-MB-435 cell lines showed no significant difference in response between 
B7-H3 knockdown and B7-H3 silenced cells upon treatment with Everolimus. 
Although both cell lines used are triple negative and initially have a high expression 
of the B7-H3 protein, they have characteristic genetic compositions with different 
gene expression patterns contributing to their response. This is further exemplified by 
the fact that although both cell lines showed an increased sensitization to API-2 
treatment in the B7-H3 knockdown cells, no correlation with respect to activity levels 
of proteins in the pathway upon API-2 exposure has so far been found in the MDA-
MB-435 cells. Clearly, the identification of mechanisms behind the increased 
sensitization to API-2 treatment shown in the MDA-MB-435 B7-H3 silenced cells 
can add further aspects to our findings. Moreover, the knockdown cells showed 
decreased proliferative rate in both cell lines, as observed by their different cell 
seeding number. This was also evident in the culturing of the cells where all 
knockdown cells had a slower growth than their B7-H3 expressing counterparts. This 
further emphasizes the importance of elucidating the function of B7-H3 in cell 
signaling.   
 
Several of the anti-cancer drugs in our screen targeted the same proteins in the cells, 
however they induced different cellular response. For example, in addition to API-2 
and Everolimus, there were two other compounds targeting Akt and mTOR, namely 
Akt 1/2 kinase inhibitor and Temsirolimus respectively. The MDA-MB-435 cell 
variants were non responsive to the Akt 1/2 kinase inhibitor (as demonstrated by a 
growth inhibition effect below 20 %), whereas the MDA-MB-231 cell variants had a 
minor response with 23 % (TR33) and 21 % growth inhibition at the highest 
concentrations. This was in contrast to the response to API-2 which induced a growth 
inhibition ranging from 31- 45 % in the MDA-MB-435 cells and 50-63 % in the 
MDA-MB-231 cells at the highest concentration (Table 4). The mechanism of action 
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of both Akt inhibitors is poorly understood, but it has been implicated that both 
substances bind to the PH-domain of Akt, thus preventing its translocation and 
activation at the plasma membrane (76). The Akt 1/2 kinase inhibitor has isozyme 
selectivity, and more effectively inhibit Akt 1 and Akt 2, respectively. Moreover, this 
inhibitor has also shown to have no effect in Akt that lack the PH-domanin (140). 
Because both inhibitors work in a PH-dependent manner, it is possible that these cell 
lines have a high expression of Akt 3, which is more effectively inhibited by API-2. 
Similarily, both Temsirolimus and Everolimus are Rapamycin analogues, and 
putatively inhibits mTOR1 through the same mechanisms. In theory analogue drugs 
are expected to exert the same effect, however there are many mechanisms that might 
explain variations between drug responses. The drugs may bind to their target protein 
with different affinity or have different stability in the cells. Furthermore, cells may 
harbor a specific mutation in the target protein which renders it resistant to the drug 
by interfering with drug binding, and thus make it less/not effective. The drugs may 
also have several mechanisms of action in the cell, inhibiting similar protein 
structures, and thus show differences in effectiveness. Therefore both the genotype of 
the cells and properties of the drug may influence the response to the drugs (38). The 
genetic composition of the cell may also interfere with drug efficacy. For example, 
Everolimus is a good substrate for the multidrug-resistance pump P-glycoprotein, and 
an intrinsic high expression of this protein might render the cells less responsive to 
this anti-cancer drug (129).   
 
In this thesis, we have investigated the drug response in two triple negative breast 
cancer cell lines with respect to their expression of the B7-H3 protein. Triple negative 
breast cancer has an aggressive clinical course, and because they do not express any 
known molecular markers that are developed treatment against, their systemic 
management is limited to conventional chemotherapy. They represent a 
heterogeneous group of cancers, as our results demonstrate, where two triple negative 
cancer cell lines showed different responses upon treatment with different drugs. This 
is probably due to diverse genomic backgrounds in the cell lines, which contributes to 
their response. The classification of biomarkers that can identify the patients that will 
benefit from a treatment, or not, is therefore crucial. Moreover, the identification of 
novel effective therapeutic markers that can better target these aggressive tumors is 
important to improve the outcome for these patients. The future of breast cancer 
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treatment aims to develop individual treatment strategies based on the patient’s 
genomic and phenotypic background, and thus to personalize the therapy. As 
demonstrated by the different response in two triple negative breast cancer cell lines 
in the present thesis, this could have a major impact on improving diagnosis and 
finding the ideal treatment regimen. However, the screening of individual patients to 
achieve their genomic profile presents a big challenge with respect to cost and work, 
and is not performed routinely today. Furthermore, more knowledge about the 
molecular mechanisms in breast cancer is needed before this can become reality. 
Targeted therapy is indeed a step towards a more personalized treatment strategy, but, 
as the present thesis illustrates, it is important to identify biomarkers, both genes and 
molecules, which can help predict outcome, response to treatment or serve as a 
therapeutic target.  
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5. Conclusion 
 
Resistance to treatment is a general problem in advanced breast cancer, and increased 
knowledge about the underlying molecules and pathways involved in resistance is 
needed to improve the outcome for these patients. The identification of biomarkers of 
prognostics and predictive value is crucial in order to improve current cancer 
management.  
 
In this thesis we showed that the silencing of the B7-H3 protein sensitized triple 
negative metastatic cancer cells to two small molecule inhibitors targeting the 
PI3K/Akt/mTOR pathway, a pathway that is frequently activated in breast cancer. 
Further investigation showed that the increased sensitivity was associated with B7-H3 
induced regulation of molecules in this pathway. In the MDA-MB-231 knockdown 
cells a decrease in phosphorylated Akt was seen upon API-2 treatment as compared to 
their B7-H3 expressing counterparts. This was also reflected downstream of Akt with 
lower activity levels of the protein translation activator p70S6K. In the Everolimus 
treated MDA-MB-231 cells there was also a reduction in the phosohorylation levels 
of p70S6K. This might indicate a similar B7-H3 mediated mechanism of sensitization 
to both API-2 and Everolimus. The inhibition of mTOR induced a compensatory 
upregulation of phosphorylated Akt (ser473) in both the B7-H3 expressing and the 
B7-H3 knockdown cells. This effect might explain the lower effect of Everolimus 
treatment in the cell line, as compared to API-2. This exemplified that a combinatorial 
approach might be necessary to abrogate malignant pathways and circumvent 
resistance induced by intracellular crosstalk and pathway redundancy. In addition, the 
understanding of the underlying molecular mechanisms of drug response is crucial to 
rationally combine treatment to the individual tumors.   
 
The previously observed relationships between B7-H3 expression and advanced 
disease and poor prognosis indicate that this protein can serve as a prognostic and 
predictive biomarker. Our results, together with the identification of the involvement 
of the B7-H3 protein in metastasis and chemoresistance, further imply that it might 
also be a suitable therapeutic target to increase the effect of anti-cancer drugs. 
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6. Future perspectives 
 
The work in the present thesis demonstrated that knockdown of the B7-H3 protein 
increased the sensitivity of triple negative breast cancer cell lines to two small 
molecule inhibitors. To confirm these findings and to verify that our results reflect an 
important functional property of the B7-H3 protein, this needs to be investigated 
further in a larger panel of cancer cell lines. Furthermore, the experiments should also 
be validated in 3D culturing systems and ultimately in xenograft models, where the 
microenvironmental influence can be taken into consideration.  
 
In previous studies, the silencing of the B7-H3 protein mediated an abrogation of the 
Jak2/Stat3 pathway. In this thesis we identified a role of the B7-H3 protein in the 
PI3K/Akt signaling pathway. The finding of several molecules that are apparently 
directly or indirectly regulated by B7-H3 may in turn help elucidate the exact 
biological function of this protein. It would therefore be of interest to investigate 
whether any molecules in the Jak2/Stat3 pathway might be affected upon API-2 and 
Everolimus treatment, as this could help unravel possible signaling crosstalk between 
these two pathways and the link to the B7-H3 protein.  
 
In this thesis the activity levels of several proteins in the PI3K/Akt/mTOR pathway 
were investigated, and we intend to further confirm these findings on order to make 
the results suitable for publication. Also, the investigation of the cellular mechanisms 
underlying the increased sensitization of API-2 in the MDA-MB-435 cells is ongoing 
and the results may add further aspects to the biological role of the B7-H3 protein.  
 
We have here investigated the treatment response of the cells at the protein level. It 
would be of interest to study the mRNA and miRNA genome wide expression profiles 
in the B7-H3 cell line models to learn more about the pathway implicated by B7-H3. 
In addition, we can further evaluate this by exposing the cell variants to API-2 and 
Everolimus. As we have illustrated in our work, cellular signaling is complex, and 
investigating alterations in gene expression levels might help create a more complete 
picture of the B7-H3 protein in cell signaling, and any findings can then be confirmed 
at the protein level by Western blot analysis. The integration of this knowledge with 
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current information can also help elucidate important mechanisms of resistance to 
therapy and metastasis.  
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APPENDIX A: Reagents and equipment 
 
The reagents and equipments utilized during cell culturing and drug screening are 
listed in Table A1, reagents for the Lysis buffer are listed in Table A2 and reagents 
for Western blot analysis are listed in Table A3.  
 
Table A1. Reagents and equipment used in the drug screening and in cell culturing in general 
Name Vendor Catalog number 
Corning® 100x20mm Petri Dish with Cover Corning 70165-102 
Seriological pipette (1mL) Sarstedt 86.1251.001 
Fisherbrand Disposable Serological Pipettes 
(5mL) 
Fischer Scientific 13-676-10H 
Fisherbrand Disposable Serological Pipettes 
(10mL) 
Fischer Scientific 13-676-10J 
Fisherbrand Disposable Serological Pipettes 
(25mL) 
Fischer Scientific 13-676-10K 
Reagent and centrifuge tube, 15 mL Sarstedt 62.554.502 
Reagent and centrifuge tube, 50 mL Sarstedt 62.547.254 
Bürkner Chamber Carl Roth GmbH T730.1 
Dulbecco’s Modified Eagles Medium Sigma-Aldrich D5671 
Invitrogen HEPES Life Technologies 15630056 
GIBCO®Glutamax Life Technologies 35050038 
GIBCO® Distilled Phosphate Buffered Saline 
(PBS) 
Life Technologies 14190094 
GIBCO® Fetal Bovine Serum (FBS) Life Technologies 26140-079 
GIBCO®Pencillin Streptomyces 
(Pen-Strep) 
Life Technologies 15140-122 
0,25% Trypsin-EDTA Life Technologies 25200-056 
GIBCO®GlutaMAX Life Technologies 35050038 
GIBCO®destilled H2O Life Technologies 10977-035 
Puromycin (10mg/ml) Sigma-Aldrich P9620-10ML 
Dimethyl Sulfoxide (DMSO) Thermo Scientific 20688 
384 well plates Greiner bio-one 781098 
Drug plates 
Medical Biotechnology VTT 
in Finland 
Not commercially 
avaliable 
CTG luminescent cell viability assay Promega G7572 
Corning incorporated Corning
®
 Costar
®
 96 
well cell culture plate 
SIGMA-ALDRICH CLS3596-50EA 
Pierce® BCA Protein Assay Kit Thermo Scientific 23225 
Triciribine (API-2) SIGMA-ALDRICH T3830-5MG 
Everolimus SIGMA-ALDRICH 07741-10MGF 
Cell scrape 
TPP Techno Plastic Products 
AG 
99002 
 
Table A2. Reagents used in the lysis buffer (LB) 
Name Vendor Catalog number 
Sodium orthovanadate Na3VO4  SIGMA-ALDRICH S6508 
Pepstatin A SIGMA-ALDRICH P4265 
cOmplete, Mini Protease Inhibitor Cocktail Tablets (PIC)  Roche 04693124001 
phospho-STOP Phosphatase inhibitor cocktail tablets Roche 04906837001 
Phenylmethylsulfonyl fluoride (PMSF) Roche 11359061001 
Aprotinin SIGMA-ALDRICH A4529 
Leupeptin SIGMA-ALDRICH L2884 
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Table A3. Reagents and equipment used in the Western blot analysis 
Name Vendor Catalog number 
NuPage
®
 Sample Reducing 
agent (10x) 
Life Technologies NP0009 
NuPage
®
 LDS Sample Buffer 
(4x) Invitrogen
TM
 
Life Technologies NP0008 
NuPage® Bis-Tri 
Polyacrylamid gel 
Life Technologies NP0321BOX 
XCell SureLock® Mini-Cell and 
XCell II™ Blot Module 
Life Technologies EI0002 
NuPage® MES SDS Running 
Buffer 
Life Technologies NP0002-02 
GIBCO®UltraPure™ 1M Tris-
HCI, pH 7.5  
Life Technologies 15567-027 
Watman
TM
 chromatography 
papers (3mm) 
GE Healthcare 3030-931 
Immobilon® Transfer 
Membranes Polyvinylidene 
Difluoride (PVDF) (0.45µm 
pore size) 
Millipore IPVH00010 
Tween
®
20 Merck 8.22184.0500 
Albumin for bovine Serum 
(BSA) 
SIGMA-ALDRICH A3294-50G 
Nonfat dry milk (Skimmed milk 
powder) 
TINE - 
SuperSignal West Dura 
Chemiluminescent Substrate 
Thermo Scientific 34075 
Tris Bio-Rad 161-0716 
Glycin Merck 1042010100 
SeeBlue®Plus2 Prestained 
Standard (1x) (Ladder) 
Invitrogen LC5925 
Akt antibody Cell signal 9272 
Phospho-Akt (Thr308) Cell signal 9275L 
Phospho-Akt (ser473) Cell signal 4051S 
Phospho-Bad (ser112) Cell signal 9296S 
Phospho-GSK-3β (ser9) Cell signal 9336S 
Phospho-mTOR (Ser2448) Cell signal 
2971S 
 
Phospho-PDK1 (Ser241) Cell signal 3061 
Phospho-elF4E Cell signal 9741S 
Phospho-p70S6K (Thr389) Cell signal 9206S 
Calbiochem
®
 Anti-α-Tubulin 
Mouse mAb (DM1A) 
Millipore CP06 
β-actin Abcam ab8229 
Human B7-H3 R&D systems AF1027 
Polyclonal Rabbit Anti Goat 
Immunoglobulins/HRP 
Dako P0449 
Polyclonal Rabbit Anti Mouse 
Immunoglobulins/HRP 
Dako P0161 
Polyclonal Goat Anti Rabbit 
Immunoglobulins/HRP 
Dako P0448 
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APPENDIX B: Preparation of Lysis Buffer (LB) and 
Bovine Serum Albumin (BSA) Standard 
 
 
The stock solution used in the Lysis buffer consisted of 20 mM Tris-HCl pH 7.5, 137 
mM NaCl, 100 mM NaF, 10 % Glycerol and 1 % NP-40. The LB was prepared fresh 
prior to use according to Table B1. 
 
Table B1. Preparation of STOCK solution and Lysis Buffer (LB)  
Reagent Volume (µL) 
STOCK 714.5 
Na2VO3 (Vanadate, 200 mM) 2.5 
Leupeptin 10 
Pepstatin 10 
phospho-STOP Phosphatase inhibitor cocktail tablets (10x) 100 
Protease Inhibitor Cocktail (PIC) (7x) 143 
Phenylmethylsulfonyl fluoride (PMSF) 10 
Aprotinin 10 
Total Volume 1000 
 
 
Preparations of the BSA standards were done according to the manufacturer as listed 
in Table B2.  
 
Table B2. Diluted Albumin (BSA) Standards. Dilution scheme for Standard Test Tube Protocol and 
Microplate Procedure (Working Range = 20-1500µg/mL) (available from (104). 
BSA 
Volume of Diluent (dH2O) 
(µL) 
Volume and source of BSA 
(µL) 
Final BSA Concentration 
(μg/mL) 
A 125 
375 of Stock BSA 1500 
B 325 
325 of Stock BSA 1000 
C 175 
175 of vial A dilution 750 
D 325 
325 of vial B dilution 500 
E 325 
325 of vial C dilution 250 
F 325 
325 of vial D dilution 125 
 
 
 
 
 
 
